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CHAPTER 1 INTRODUCTION
1.1

Introduction to the ribosome

The bacterial ribosome was first described as a small particulate component of the
cytoplasm and later a ribonucleoprotein by Dr. George Emil Palade in 1955 where he
used electron microscopy to characterize the then newly-discovered organelle from rat
and chicken cells.1 This work later led Palade and two other scientists, Albert Claude
and Christian de Duve, to be awarded the Nobel Prize in physiology or medicine in 1974.
These three scientists were awarded the Nobel Prize for their work focusing on the
"discoveries concerning the structural and functional organization of the cell".2 The term
"ribosome" was later introduced by editor Richard B. Roberts in the introduction portion
of the 1958 publication "Microsomal Particles and Protein Synthesis".3
Although ribosomes were a hot subject of research in the mid-1950s and early-1960s,
focus would soon shift away from these organelles. The main challenge to be addressed
was to determine the exact mechanistic function of the ribosome, and although it was
known that the ribosomes were enzymes capable of synthesizing proteins and that they
consisted of ribonucleic acids (RNA) as well as proteins, limited technology hindered
research activity during that time period to discover detailed functions. It was also
difficult for chemists and biologists to consider that RNA could in fact catalyze reactions
since little to no information was available to support the hypothesis. It wasn't until the
1980s that evidence really began to accumulate that RNA could in fact catalyze
chemical reactions,4-6 which then led to ribosomal RNA (rRNA)-focused research well
into the beginning of the 21st century and reviving interest in ribosomes.7-10 By this time,
it was clear that the ribosome, composed of RNA and protein, was capable of performing
translation with the RNA component acting as the catalyzing force for function.
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1.1.1

Components that form the bacterial and eukaryotic ribosome

The ribosome is composed of two major subunits, known as the large and small
subunits, which are characterized by the sedimentation rate known as the Svedberg
unit.11 Through a process known as ultracentrifugation, a particle's mass, density, and
size will lead to a specific rate of sedimentation. One Svedberg (S) is equal to 10-13 s,
and the numerical value associated with a Svedberg unit is in direct relation to rate, not
weight.
In the case of the bacterial ribosome, as shown in Figure 1.1, the large subunit is
known as the 50S subunit and the small subunit is known as the 30S subunit. When the
50S and 30S subunits associate, they form the full 70S ribosome. The eukaryotic
ribosome is larger than the bacterial ribosome with a small subunit of 40S and a large
subunit of 60S, which together comprise the full 80S ribosome. As this thesis work
focuses exclusively on the bacterial ribosome, all figures and explanations will be in
reference to the E. coli system. It is important to note, however, that although the
bacterial and eukaryotic ribosomes differ in overall size, they have many essential
regions for function that are highly conserved.12
As shown in Figure 1.1, the large and small subunits of the E. coli bacterial ribosome
can be further broken down into the individual components, ribosomal RNA (rRNA) and
ribosomal proteins (rproteins). The 50S subunit comprises 5S rRNA, which contains 120
nucleotides, and 23S rRNA, which contains 2904 nucleotides. The 50S also contains 34
rproteins. The 30S subunit is made up of the 16S rRNA, containing 1542 nucleotides,
and 21 rproteins.13
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Figure 1.1 Subunits of the E. coli bacterial ribosome.13 (A) The large 50S subunit
(2AW4), which is composed of 23S rRNA in yellow, the 5S rRNA in red, and 34 rproteins
in green. (B) The small 30S subunit (2AVY) is composed of 16S rRNA in grey and 21
rproteins in cyan. (C) Ribosome association of the large and small subunits forms the full
70S ribosome (2AVY, 2AW4).
As described in Section 1.1, the detailed function of the ribosome was not
mechanistically understood until the latter portion of the 20th century, and although there
is still much to learn about this essential organelle, work has been completed to
determine the order of factors and components necessary for ribosomal assembly. The
bulk of this work was performed by Masayasu Nomura and co-workers.14 His work
revolved around the accepted premise that ribosomal subunits are self-assembling. His
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group performed a series of partial reconstruction experiments in which they would
systematically remove a factor, or protein, essential to the self-assembly function
individually. If one macromolecular component is left out, the entire subunit could not
self-assemble and one could then observe which portions did not assemble. This not
only provided an order of assembly for each component of the macromolecule, but also
the significance of individual factors relative to one another.
1.1.2

Function and significance of the bacterial ribosome

The central dogma of molecular biology, as illustrated in Figure 1.2, was initially
described by Francis Crick in the late 1950s to explain the flow of genetic information
amongst living organisms, and later published in the early 1970s. To summarize briefly,
DNA first produces complementary DNA through a process called replication. Then,
DNA can further produce RNA via transcription. Finally, RNA produces proteins through
a process called translation.15 Translation is performed by ribosomes, in which the
reaction is catalyzed primarily by RNA. Ribosomes are therefore essential for cellular
vitality.

Figure 1.2 The central dogma of molecular biology.15 This chart shows the flow of
genetic information as expressed by living organisms. DNA can undergo replication to
produce more DNA, and RNA can undergo reverse transcription to make DNA. DNA can
also produce RNA through a process called transcription. RNA can make proteins
through translation.
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The biological role of the ribosome was first understood by Paul Zamecnik when he
used carbon-14 labeling of amino acids and found them incorporated into proteins when
studying the ribosome.16 He was later credited with the discovery of tRNA, an intricate
part of the translation system.17-19
Ribosomes perform protein synthesis in a finite series of steps, namely, initiation,
elongation, and termination, in an overall process known as translation. As shown in
Figure 1.3, initiation begins when the 30S subunit encounters a single-stranded mRNA
transcript. This encounter occurs when the 30S is charged with fMet-tRNAfMet. The
recognition of the codon AUG is not the only step necessary to begin initiation. The
mRNA transcript must also have the Shine-Dalgarno sequence20 incorporated
approximately 10 nucleotides upstream of start codon sequence. This sequence is
purine rich and complements a pyrimidine-rich "anti-Shine Dalgarno" sequence located
on the 16S rRNA.20
This binding motif allows the 30S to identify the correct start codon of the mRNA
transcript for translation. Initiation factors are also crucial, as they are responsible for reactivating 70S ribosomes for protein synthesis. In bacteria, there are several monomeric,
water soluble protein factors that aid translation. Initiation factor one (IF-1) assists
initiation factor three (IF-3) in binding to the 30S subunit of an inactivated 70S ribosome
to promote subunit dissociation. IF-3 then recruits new mRNA to bind the 30S.
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Figure 1.3 Translation initiation of the bacterial ribosome. A) An inactivated 70S
ribosome is approached by IF-3, which promotes subunit association. IF-3 remains
bound to the 30S subunit. B) An mRNA with the start codon AUG and Shine-Dalgarno
sequence upstream of the start codon sequence is recruited to the 30S subunit along
with IF-1 and IF-2-GTP-fmet-tRNAfMet complex. This combination forms the 30S initiation
complex. C) IF-1 and IF-3 are released, allowing for subunit association, and hydrolysis
of GTP releases IF-2. The 70S initiation complex is formed, allowing for elongation to
begin.
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Initiation factor two (IF-2) complexed with GTP, fMet-tRNAfMet, and mRNA is then able
to bind to the reactivated 30S subunit (as described earlier in conjunction with the
complement binding of the Shine Dalgarno – anti-Shine Dalgarno sequences). IF-1
binds to the aminoacyl-tRNA site (A site), located in h44 of the 30S subunit,12 to prevent
premature binding of tRNA. IF-3 then proceeds to destabilize any tRNA that lacks the
three G-C base-pairs of the anticodon stem of the fMet-tRNAfMet in order to discriminate
between matched and mismatched codons. This step prevents the incorporation of
erroneous tRNAs.
Once the appropriate AUG start codon is coupled with the fMet-tRNAfMet, IF-1 and IF-3
dissociate from the 30S subunit allowing subunit association with the 50S to occur.21-22
When subunit association takes place, IF-2 is stimulated causing hydrolysis of its bound
GTP. A conformational change of the 30S releases IF-2.
To briefly summarize translation initiation, the focus is on the activation of the 30S
subunit before any subunit association with the 50S subunit occurs. This process works
to identify the start sequence of an mRNA transcript. There are three protein factors
responsible for facilitating this process, which are summarized in Table 1.1.
Table 1.1 Proteins responsible for translation initiation in bacteria
Initiation Factor
Function
IF-1
Assists binding of IF-3 to the 30S subunit
of the inactivated 70S ribosome. It also
binds to the A site, preventing tRNAs from
prematurely binding.
IF-2
Acts as a GTPase and aids in the binding
of the initiator fMet-tRNAfMet and GTP to
the 30S subunit.
IF-3
Releases mRNA and tRNA from the 30S
subunit of the inactivated 70S ribosome. It
also facilitates new mRNA binding and
prevents premature binding of tRNA.
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The second stage in translation is known as elongation, which works in a cyclic
fashion requiring three main steps with the end goal of producing growing peptide
chains. These steps are decoding, transpeptidation, and translocation. As shown in
Figure 1.4, decoding occurs when EF-Tu-GTP binds to an aminoacyl-tRNA.23-24 This
complex can then bind to the ribosome. Hydrolysis of GTP in this complex facilitates
binding of the aminoacyl-tRNA to the ribosomal A site. This binding event is based on
codon-anticodon complementarity, and when the complex forms, EF-Tu and hydrolyzed
GDP are released. EF-Tu facilitates tRNA binding in an efficient manner.25-26 GDP is
replaced by EF-Ts, allowing for a new GTP to bind EF-Tu (thereby re-releasing EF-Ts).
To clarify, EF-TS works to recycle EF-Tu for elongation by removing the hydrolyzed
GDP and recruiting a fresh GTP.

Figure 1.4 Translation elongation of the bacterial ribosome. Elongation is broken
down into three steps: decoding, transpeptidation, and translocation. These steps work
in a cyclic fashion in conjunction with the three elongation factors (EF-Tu, EF-Ts, Ef-G,
not pictured) until the polypeptide is complete.
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The second major step of elongation is transpeptidation.27-29 Peptide-bond formation
occurs during this process. Bond formation occurs with the nucleophilic displacement of
the tRNA bound to the peptidyl transferase-tRNA site (P site) by the amino group of the
aminoacyl-tRNA in the A site. The peptidyl transferase center (PTC) is located entirely in
the 50S subunit and is the sole region where peptide-bond formation occurs.
The third and final step of elongation, prior to cycling back to decoding, is
translocation, in which the uncharged tRNA in the P site is transferred to the exit site (E
site). At the same time, the peptidyl-tRNA in the A site is moved to the P site, which
allows the ribosome to repeat the elongation cycle for the next amino-acylated tRNA.
Translocation works in a ratchet-like motion between the 30S and 50S subunits.30-32
Note that ratchet-like motion refers to the tool known as a ratchet, which is latched onto
a socket. The socket will rotate a bolt into a continuous clock-wise or counter-clockwise
motion. It's important to understand that the ratchet tool itself only moves in a repetitive
forward-reverse motion and does not actually make the full revolution that the socket
makes in order to tighten or loosen the corresponding bolt. When the motion of the
ribosome is referred to in a ratchet-like motion in this report, please note that the two
subunits are moving back and forth analogous to the ratchet tool, not in continuous
revolution as in the function of the socket.
Translocation is facilitated by EF-G.33-34 EF-G is able to promote translocation through
GTP binding and hydrolysis, just like EF-Tu had done earlier in the elongation cycle. In
fact, EF-G and EF-Tu have a very intricate balance as they bind to the same site of the
ribosome, and so only one process can occur at any given time point within a single
ribosome. Table 1.2 summarizes the proteins responsible for elongation. Note that these
proteins have eukaryotic analogues not discussed in this report.
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Table 1.2 Proteins responsible for translation elongation in bacteria
Elongation Factor Function
EF-Tu
Binds the aminoacyl-tRNA and GTP
EF-Ts
Displaces GDP from EF-Tu
EF-G
Stimulates translocation through GTP binding and
hydrolysis
The third and final stage of translation, termination, occurs when the ribosome
encounters a stop-codon sequence. In this case, there are three possible codons, unlike
that of the single start-codon sequence that contains one possible code. In bacteria, the
stop-codon possibilities are UAA, UAG, and UGA, and when the ribosome encounters
any one of those three codes, there are no aminoacylated tRNAs that complement those
codons. As shown in Figure 1.5, this event stimulates the release of the polypeptide
chain, which can then move on to fold into a functional protein. The ribosome then
begins the cycle again by dissociating into the 30S and 50S subunits. In order to
facilitate termination, proteins known release factors work to recognize the termination
codon sequences. RF-1 recognizes UAA and UAG. RF-2 recognizes UAA and UGA.35-36
These factors facilitate the release of the newly synthesized peptide. RF-3 complexed to
GTP then binds to the ribosome and induces hydrolysis.37-38 This step allows the release
of RF1 or RF2 based on the termination sequence.
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Figure 1.5 Translation termination of the bacterial ribosome. The release factor one
(RF-1) or release factor two (RF-2), not shown, recognize the stop codon UAA. This
stimulates the recruitment of RF-3 bound to GTP, which, upon hydrolysis, recruits EF-G
bound to GTP and the ribosome recycling factor (RRF) upon its release. Upon a second
hydrolysis of the GTP bound to EF-G, the mRNA, remaining tRNA, and termination
factors are released, leaving an inactivated 70S ribosome.
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Ribosome recycling factor (RRF) can then bind to the A site in conjunction with EF-GGTP complex.37 The hydrolysis of EF-G allows RRF to be translocated to the P site, in a
similar fashion described in the elongation segment of this process, which shifts the
remaining tRNAs out and into the E site. This process ultimately releases the RRF and
hydrolyzed EF-G-GTP complex with mRNA, leaving behind an inactive 70S ribosome.
All of the termination proteins responsible for translation termination in bacteria are listed
in Table 1.3.
Table 1.3 Proteins responsible for translation termination in bacteria
Termination Factor Function
RF-1
Recognizes UAA and UAG stop codons
RF-2
Recognizes UAA and UGA stop codons
RF-3
Releases RF-1/RF-2 through GTP hydrolysis
RRF
In conjunction with EF-G to induce subunit
dissociation

The inactive ribosome can be recycled by reactivation with the binding of IF-3 as
described in the initiation portion of the translation process and an entirely different
protein can be synthesized. Note that translation as described here does not account for
exceptions such as the engineering or incorporation of non-canonical or modified amino
acids or different charged tRNAs with variable codon sequences outside the genetic
code. These exceptions will not be covered in this work; although, it is important to note
that they do exist.39-40 Without the ribosome's ability to carry out translation, new proteins
could not be made. These proteins are very diverse and are synthesized based on the
cell's need for them in order to survive. Organisms need living cells to survive, making
ribosomes significant for organism vitality.
1.1.3

Ribosomal RNA structure and modifications

Ribosomal RNA is essential due to its catalytic activity in protein synthesis. Although
this fact wasn't readily realized when the ribosome function was initially discovered, it
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was later found that removing rproteins from ribosomes followed by activity assays
provided evidence that the rRNA was responsible for the catalytic activity.41-42
Information on rRNA expanded greatly when the secondary structures of the 5S (Figure
1.6), 16S (Figure 1.7), and 23S rRNAs (Figure 1.8) were determined.12,

43-44

Finally,

solving the crystal structures of ribosomes verified the role of rRNA as the catalytic
domain for translation.45-57

Figure 1.6 Secondary Structure of the 5S rRNA. This figure was adapted from the
Comparative RNA Website (CRW) established by the Gutell laboratory.12 The 5S rRNA
does not contain modifications and is part of the 50S subunit.
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Figure 1.7 Secondary Structure of the 16S rRNA. This figure was adapted from the
Comparative RNA Website (CRW) established by the Gutell laboratory.12 Domain
nucleotide allocations were determined from Woese and coworkers43 and work from Xu
and Culver.44 Modified RNA nucleotides are labeled with arrows in each of the four
domains according to their assigned color; for an example, modifications found in
domain I are visualized with red arrows. Literature responsible for modification
determination and discovery can be found in Table 1.4.
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Figure 1.8 (shown on two pages) The secondary structure of the 23S rRNA. This
figure was adapted from the Comparative RNA Website (CRW) established by the Gutell
laboratory.12 Domain nucleotide allocations were determined from Steitz and coworkers58
and work from Gutell and Noller.59 Modified RNA nucleotides are labeled with arrows in
each of the six domains according to their assigned color; for an example, modifications
found in domain II are visualized with blue arrows. Literature responsible for modification
determination and discovery can be found in Table 1.5.
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Ribosomal RNA was also discovered to contain modified bases that were incorporated
post-transcriptionally. References correlating to each of these modifications can be
found in Table 1.4 and Table 1.5. Of these 35 modifications within the 23S and 16S
rRNAs, approximately two-thirds of them are classified as methyltransferases. The
remaining third are pseudouridine synthases, an enzyme isomerase classification.
Removing these modifications have been shown to diminish function60-61 such as subunit
association.62 Table 1.4 gives a list of all of the modifications present in E. coli 16S
rRNA. Included in the table are the enzymes responsible and their classification (MT:
methyltransferase; PS: pseudouridine synthase). Table 1.5 gives the same information
for the 23S rRNA modifications. The 5S rRNA does not contain modified bases.
Table 1.4 Nucleotide modifications in E. coli 16S rRNA
Base Modification Position
Enzyme
Enzyme References
Class
2
63-66
G
mG
966
RsmD
MT
7
67-69
G
mG
527
RsmG
MT
2
64-65, 70-72
G
mG
1207
RsmC
MT
64, 71, 73
G
m2G
1516
RsmJ
MT
5
74-76
C
mC
967
RsmB
MT
77-79
1407
RsmF
MT
C
m5C
4
80-81
C
m Cm
1402
RsmH
MT
2
82-88
A
m 6A
1518
RsmA
MT
2
82-88
A
m 6A
1519
RsmA
MT
3
89-90
U
mU
1498
RsmE
MT
91-93
Ψ
U
516
RsuA
PS
MT: methyltransferase; PS: pseudouridine synthase
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Table 1.5 Nucleotide modifications in E. coli 23S rRNA
Base Modification Position
Enzyme
Enzyme
Class
1
G
mG
745
RlmA(I)
MT
G
m2G
1835
RlmG
MT
G
m7G
2069
RlmKL
MT
G
Gm
2251
Mrm1
MT
C
m5C
1962
Rlml
MT
C
Cm
2498
RlmM
MT
C
s2C
2501
6
1618
RlmF
MT
A
mA
A
m6A
2030
RlmJ
MT
A
m2A
2503
Cfr
MT
Ψ
U
746
RluA
PS
5
U
mU
747
RlmCD
MT
Ψ
U
955
RluC
PS
Ψ
U
1911
RluD
PS
Ψ
U
1915
RluD
PS
3
mΨ
U
1915
RluH
MT
Ψ
U
1917
RluD
PS
U
m5U
1939
RlmD
MT
U
D
2446
Ψ
U
2457
RluE
PS
Ψ
U
2504
RluC
PS
U
Um
2552
RlmE
MT
Ψ
U
2580
RluC
PS
Ψ
U
2604
RluF
PS
Ψ
U
2605
RluB
PS
MT: methyltransferase; PS: pseudouridine synthase
1.1.4

References
94-96
64, 97-98
64, 99-101
102
103-105
81, 106
107
108
109-110
111-117
118-123
124
125-128
127, 129-135
127, 129-135
132, 136-137
127, 129-135
138-141

142-143
125-128
144-148
125-128
142, 149-150
142, 151

Antibiotic resistance associated with targeting bacterial ribosomes

Antibiotic resistance is an increasing problem in the medical world, leaving previously
potent drugs unusable to treat common bacterial infections.152 Approximately half of the
known antibiotics target the bacterial ribosome; however, target modification at the rRNA
level is a common mechanism leading to resistance.153 To add to this problem, many of
the current antibiotics have overlapping binding sites on the ribosome, leading to
multidrug resistance as illustrated in Figure 1.9. The bacterial ribosome is an ideal drug
target because it is an essential organelle needed for cell survival.

19

Figure 1.9 Antibiotic binding locations on the 50S and 30S bacterial subunits. The
50S subunit (left, yellow, 2AW4) has the peptidyl transferase center (PTC) highlighted in
light purple mesh and helix 69 (H69) in cyan mesh. The 30S subunit (right, grey, 2AVY)
has the aminoacyl site (A site) in red mesh. The following color codes are used: (left,
50S) red, thiostrepton;154 green, avilamycin;155 blue, macrolide antibiotics;156 purple,
streptogramin A,156 and burgundy, thermorubin on H69;157 (right, 30S) blue,
tetracycline;158 purple, pactinomycin;159 orange, hygromycin;159 red, spectinomycin B;160
green, aminoglycoside antibiotics;161 burgundy, thermorubin.157
The antibiotic resistance problem is associated with several issues, which is why it is
so difficult to overcome this challenge. These issues include the general non-compliance
of patients when it comes to sticking to antibiotic regiments. Many people stop taking
antibiotics when they feel better, which gives remaining bacteria the opportunity to
develop a tolerance to these drugs. Another issue involves over-exposure of antibiotics
in everyday items like soap and food. One such example is triclosan, an antibiotic that's
been used in everyday commercial products such as detergents, soaps, and toothpaste
for the past 30 years.162 It was initially used as a pesticide and found to be present in
over 75% of human urine samples tested in 2008.162 The last major issue contributing to
resistance is general bacterial exposure. From an evolutionary standpoint, bacteria will
develop resistance to toxins, or antibiotics, produced from other bacteria in order to
survive their own environment. Most of the antibiotics known to us today were derived
from natural products produced by bacteria. In efforts to avoid problems already
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associated with antibiotic resistance in regards to the ribosome, the challenge is to
identify novel regions that are still crucial for overall function but not currently targeted by
natural compounds.
1.2

The 23S ribosomal RNA and helix 69

1.2.1

The 23S ribosomal RNA domains

The 23S rRNA is located within the 50S large subunit as shown in Figure 1.1A. It
contains 2,904 nucleotides13 and is subdivided into six different domains.59 Although the
literature shows the domain nucleotide allocations at slightly different locations,163 the
nomenclature developed by Steitz and coworkers58 in conjunction with Noller and
Gutell59 is used in this thesis (Figure 1.8). Within the 23S rRNA of the bacterial
ribosome, there are 25 modifications to the canonical RNA base (Table 1.5).164-167
Nearly half of these modifications are pseudouridine, modified post-transcriptionally by
various pseudouridine synthases, of which nine are located within domains II, IV, and V.
1.2.2

Helix 69 interactions and modifications associated with its structure

Helix 69 (H69 with a capital H denoting location within the 50S) has a stem-loop motif
located near the decoding region,55 and is a critical component of the protein synthesis
machinery.168-169 H69 contains a highly conserved modified nucleotide, pseudouridine
(Ψ), which plays a role in rRNA structure and function as shown in Figure 1.10.

12, 170-171

In the bacterial ribosome, these modifications are located in the loop region of H69, and
there are three pseudouridines present at positions 1911, 1915, and 1917. The 1915position Ψ is methylated.
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Figure 1.10 Secondary structures of H69 analogues. The wild-type bacterial H69
(left),12 modified (middle), and unmodified (right) analogues were used this work.
Helix 69 is an interesting drug target because its conservation suggests that bacteria
need it for proper function in essential ribosomal processes. This would theoretically
mean that a bacterium is less likely to make changes to the structure in order to develop
resistance mechanisms. The location of H69 at the interface of the ribosomal subunits,
as shown in Figure 1.11, is also of interest, since developing potent binders for this site
could disrupt subunit association, a process necessary for ribosome function.
Figure 1.11 The location of H69 relative to the 70S
full ribosome and essential translational regions.
H69, in cyan, is located at the juncture between the
30S and 50S ribosomal subunits. It makes a direct
interaction with helix 44 (h44), known as the aminoacyltRNA site (A site), in red. Its proximity to essential
translational machinery and at the interface of the two
subunits makes H69 an interesting target for further
inquiry.

The H69 region of 23S rRNA interacts with important components of the bacterial
ribosome; it forms intersubunit bridge B2a with h44 (with a lower case h to represent the
location within the 30S subunit) of the small subunit and has simultaneous interactions
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with A-site and P-site tRNAs.55, 60 Although conserved across phylogeny,12, 171 the roles
of H69 are not yet fully elucidated; however, it has been implicated in essential ribosome
functions such as ribosome recycling,172 tRNA selection,169 translational fidelity,168, 173-174
and subunit association.60,

134, 175

H69 has three modified bases, two Ψs and one 3-

methylpseudouridine (m3Ψ), which are believed to be important for ribosome function.61,
170, 175-178

Figure 1.12 shows the structures of these modified nucleosides compared to

the unmodified uridine.

Figure 1.12 Nucleoside structures of pseudouridine, 3-methylpseudouridine, and
uridine. Pseudouridine (Ψ, left) is a post-transcriptional modification of uridine (U, right).
The difference between these two structures is the 120° rotation of the base in
pseudouridine, forming a C–C glycosidic bond versus the canonical C–N glycosidic bond
shown in uridine. Three-methylpseudouridine (m3Ψ, middle) differs from Ψ only with a
methylation on the 3-position of the base.
1.2.3

The roles of helix 69 and antibiotics

As described earlier in this chapter, H69 has been implicated to have a role in
essential processes, which makes it an ideal target for antibiotics. What makes this
particular target challenging is that the exact function(s) and mechanism(s) by which it
performs its function are not entirely known, offering opportunities to learn more about
H69. In addition, evidence shows that some antibiotics, namely aminoglycosides179 and
several peptide antibiotics,180 target H69 as a secondary binding site. More recently, the
antibiotic thermorubin was found to target H69 directly; however, due to low solubility, it
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was not available for human use.157 This evidence provides a platform that H69 could be
a primary target for antibiotics as it does appear that binding, even as a secondary
target, inhibits ribosomal function. Identifying compounds that target H69 with favorable
drug properties could prove fruitful in the world of antibiotics.
1.3

RNA-ligand interactions with peptides

1.3.1

Peptides as RNA-targeting ligands

As natural building blocks of proteins, peptides make ideal ligands for targeting
novel/essential regions of the bacterial ribosome, amongst other cellular machinery,
because they are less likely to be detected as foreign invaders by an organism's immune
system. The caveat is that not all peptides make it to their target destination in their
natural state and most often require modification. This may include the incorporation of
additional functional groups or direct modifications to the peptide backbone to increase
their structural integrity, making it difficult for degradation to occur, or additional delivery
support to increase the likelihood of these ligands reaching their target.181-183
Because RNA is inherently dynamic with a high degree of conformational variability, it
is very challenging to design ligands with the specificity and affinity necessary to bind
effectively to their RNA targets. Ideally one conformation will be more pronounced than
others, allowing the opportunity for ligands to bind and produce an effect (inhibition).
Alternatively, the ligand design allows for binding to multiple conformational states.
Despite these two approaches and the challenges associated with each, peptides have
been used to target RNA with success.184
Vancomycin, a complex cyclic glycopeptide that targets gram-positive bacteria, has
been used as a last-resort antibiotic to fight particularly difficult bacterial infections such
as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile.185-186
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Vancomycin was originally isolated from Amycolatopsis orientalis by Edmund Kornfeld of
Eli Lilly in 1953.187 Peptide libraries have also been used to identify potent ligands to
RNA targets.184,

188-189

In other approaches, peptides have been combined with small

molecules in a fragment-based drug design approach. Compounds previously known to
target RNA but lost efficacy due to resistance mechanisms have been conjugated to
peptides for renewed activity.190-192 Further elaboration on a fragment-based drug design
approach will be addressed in the future directions portion of this work.
1.3.2

The future of peptides in antibiotics

Although peptides have been used to target RNA and have also been utilized as
drugs, they are challenging to work with because of difficulty crossing cellular barriers,
relatively large size, lack of stereochemical complexity, susceptibility to protease
degradation, and sometimes poor solubility. Their intended target may be inaccessible to
solvent or conformationally unavailable for binding. Such obstacles may outweigh the
desire to use these natural products in biochemical studies; however, peptides, with
amino acids as their building blocks, have a wide array of functional groups.
Furthermore, the compounds not limited to just the 20 canonical amino acids, and may
contain unnatural amino acids. Modified peptide libraries can be generated, increasing
the number of peptide ligands available to target H69 or other RNA constructs.
Increasing the complexity of the compound by incorporating different functional groups
for targeting RNA could enhance binding affinity and selectivity. In addition, changes to
the peptide backbone such as the production of peptoids can increase cellular
permeability and make these ligands more "druggable".193-196
Under the right conditions, peptides could make excellent drugs because as natural
products, they may not be perceived as a foreign entity and therefore drug resistance
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would be less efficient. According to Dale Boger, a chemist credited with identifying the
synthetic route to vancomycin (glycopeptide) production, it took approximately 30 years
for gram-positive bacteria to begin showing resistance to vancomycin (2013 Spring
National ACS meeting in New Orleans, LA).
1.4

Objectives associated with this thesis work

New functional sites on the ribosome that are not already targeted by current
antibiotics and have a lower chance of modification need to be identified. For these
purposes, helix 69 (H69) of the bacterial ribosome 50S subunit will be considered as a
novel drug target. The stem-loop motif, located near the decoding region,55 is a critical
component of the protein synthesis machinery.168-169 H69 contains a highly conserved
modified nucleotide, Ψ, which plays a role in rRNA structure and function.12, 170-171
To achieve the main goals of this project, three specific aims were developed:
Aim 1) Peptides that have specificity for bacterial H69 rRNA were identified.
Variants of the heptapeptide sequence, NQVANHQ, identified from phage-display
selections,197 were generated by using solid-phase peptide synthesis and the binding
affinity, selectivity, and stoichiometry were determined using electrospray ionization
mass spectrometry (ESI MS).
Aim 2) Biophysical and biochemical properties of the selected peptides were
determined. Peptides selected for bacterial H69 rRNA binding were characterized
(affinity, selectivity, stoichiometry) by using biophysical techniques such as ESI MS and
isothermal titration calorimetry (ITC). Circular dichroism (CD) spectroscopy and
enzymatic footprinting were also performed to attain biophysical properties of these
peptides.
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Aim 3) A dual binding mode of known antibiotics and peptides to helix 69 was
established. Work performed to identify the dissociation constant of the aminoglycoside
antibiotic neomycin with H69198 suggested the possibility of a dual binding mode with
H69 peptides. Information regarding dual binding can be used for the development of
novel compounds that incorporate both peptide and aminoglycoside components.
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CHAPTER 2 EXPERIMENTAL DESIGN UTILIZING BIOCHEMICAL AND
BIOPHYSICAL METHODOLOGIES
2.1

Abstract

In order to synthesize and identify novel peptide binders to H69, several biophysical
and biochemical methods were employed, all of which are discussed in this chapter.
First, modified variants of the parent sequence NQVANHQ had to be synthesized;
therefore, solid-phase peptide synthesis will be detailed, followed by a brief description
of each of the biophysical and biochemical methods used to investigate and characterize
peptide-RNA interactions. These methods include electrospray ionization and matrix
assisted laser desorption ionization time-of-flight mass spectrometries, circular
dichroism, and isothermal titration calorimetry. Purification of each peptide studied was
performed by using high performance liquid chromatography. Lastly, a screening assay
was designed to identify RNA-binding peptides from small pool of peptides containing six
position 1 variants. Background information including adaptations from appropriate
references will be itemized for each technique along with generic protocols within this
chapter. Details of individual experiments will be paired with data discussed in other
chapters in order to reduce unnecessary repetition within this work.
2.2

Solid-phase peptide synthesis (SPPS)

2.2.1

Introduction to solid-phase peptide synthesis

Solid-phase peptide synthesis (SPPS) was first described by Robert Bruce Merrifield in
a 1963 publication,199 which earned him the 1984 Nobel Prize in Chemistry for "his
development of methodology for chemical synthesis on a solid matrix".200 This approach
allows for the orthogonal addition of amino acids on a growing peptide chain anchored to
a solid support, and was designed to replace solution-phase peptide synthesis. Solution-
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phase peptide synthesis involved a problematic process involving multiple steps, or long
production profiles, for each addition, which ultimately reduced the yield of the final
product with each amino acid added. Details of solution-phase peptide synthesis will not
be discussed within this work.
In general, SPPS begins on the carboxyl-terminus (C-terminus) and ends on the
amino-terminus (N-terminus) to maintain the chirality of the side chains of each amino
acid added. Temporary and permanent protective groups are incorporated to maintain
control of addition location and to prevent the side chain of each amino acid from doing
additional chemistry. Once the peptide is completely synthesized, a trifluoroacetic acid
cocktail containing various scavenger chemicals is added to remove and help prevent
permanent protective groups from reattaching to the peptide. Solid-phase peptide
synthesis has the advantage of being performed at room temperature with shorter
production profiles for each addition of amino acids, allowing for a greater yield of
product.
2.2.2

Materials for solid-phase peptide synthesis and purification

Materials used in this technique included products from Novabiochem (LaJolla, CA),
an EMD Millipore company (Billerica, MA), such as the amino acids with
fluorenylmethyloxycarbonyl (fmoc) temporary protective groups as well as

O-(1H-

benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTu) and the
solid support Rink Amide AM 200-400 mesh. Organic solvents used during the synthesis
and workup such as dichloromethane (DCM), N,N-dimethylformamide (DMF), diethyl
ether,

diisopropylethylamine

(DIPEA),

piperidine,

trifluoroacetic

acid

(TFA),

triisopropylsilane, anisole, and thioanisole were obtained from Sigma-Aldrich (St. Louis,
MO). Kaiser test reactants such as ninhydrin, phenol, potassium cyanide and ethanol
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(EtOH) were purchased from Sigma-Aldrich (St. Louis, MO). Pyridine was purchased
from EMD Millipore (Billerica, MA). Tentagel solid supports, Tentagel HL NH2 HL12902
75 μm and Tentagel M NH2 10 μm, were purchased from RAPP-polymere (Tübingen,
Germany). Acetonitrile (ACN) used during the purification of peptides was purchased
from Sigma-Aldrich (St. Louis, MO).
2.2.3

Instrumentation used to perform solid-phase peptide synthesis

A Burrel Wrist-Action® laboratory shaker (Burrell Scientific LLC, Pittsburgh, PA) was
used to perform SPPS. The shaker was composed of two arms capable of holding six
vessels in each arm. Vessels, which varied in size for different scales of synthesis, were
made of glass and contained a glass frit. The vessels also contained a Teflon stopcock
and cap. A rubber hose and water vacuum unit was also engineered to safely remove
organic solvents during the wash steps of SPPS. The entire reaction and all equipment
and materials were used inside a chemical-safe hood with constant ventilation.
2.2.4

Protocol of solid-phase peptide synthesis

Manual peptide synthesis using standard fmoc chemistry199 as the temporary
protective group was utilized throughout this work. The solid support used varied based
on the purpose of the synthesis. Peptides used for electrospray ionization mass
spectrometry, circular dichroism, and isothermal titration calorimetry required amidation
on the C-terminus (RINK Amide AM 200-400 mesh solid support) to simulate the parent
sequence identified from the parent structure (NQVANHQ197) from previous phage
display experiments. Peptides used in the screening assay in which the solid support
was still required for selection and visualization, were synthesized on a Tentagel solid
support and the modifications to the synthesis described in this section are highlighted in
Section 2.8.2.
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SPPS began with the swelling of the solid support (beads) in DCM. Deprotection of the
fmoc group from the solid support, when the solid support actually contained a
temporary protective group, took place using 20% piperidine base in DMF as shown in
Figure 2.1.

Figure 2.1 Deprotection of fmoc temporary protective group. A chemical scheme
illustrating how 20% piperidine in DMF solution removed the fmoc protective group from
the solid support resulting in the availability of primary amine for amino acid coupling.
Beads were washed ten times at 10x resin volume using DMF prior to the addition of
amino acids containing both temporary fmoc and permanent protective groups, and the
synthesis took place in DMF. Amino acids were added in order from the carboxylterminus to the amino-terminus. A solution containing 3 eq. of the protected amino acid,
3 eq. HBTu, and 6 eq. of DIPEA was added to the peptide vessel and shaken for a
minimum of 2 h. Figure 2.2 gives the chemistry associated with a coupling event using
fmoc-Gly-OH as the amino acid being coupled to the solid support.
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Figure 2.2 Coupling of an amino acid using HBTu and DIPEA. The amino acid
glycine with fmoc protective group is added to the vessel with HBtu and DIPEA. The
DIPEA deprotonates the carboxyl group of the amino acid producing a negative charge.
HBTu is then free to couple to the amino acid producing urea as a byproduct. The
primary amine from the solid support is then able to attack the carbonyl of the HBTu
bound to the amino acid, freeing the HBTu and coupling to the amino acid.
The fmoc temporary protective groups associated with each amino acid were removed
with the dilute piperidine solution in DMF and washed ten times at 10x resin volume with
DMF prior to the addition of the next amino acid. The Kaiser test,201 described in Section
2.2.5, was also used to determine whether coupling or decoupling had taken place after
each step in the synthesis. Note that this test works specifically on primary amines and
the results are qualitative, and should therefore only be used as a general consensus of
synthesis productivity; that is, since no reaction goes to 100% completion, beads may
show incomplete coupling/decoupling in a mixture with beads that showed the
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anticipated result. Additionally, synthesis with anything other than primary amines
exposed after decoupling, such as proline, gave indeterminate results.
Once all amino acids were successfully added to the solid support, see Figure 2.3, the
beads were washed ten times at 10x resin volume each with DMF, DCM, and diethyl
ether, and allowed to dry overnight. After complete drying, treatment with 94:2:2:2 TFA:
triisopropylsilane: anisole: thioanisole was used to cleave the permanent protective
groups from the amino-acid side chains and solid support. An instruction manual from
Applied Biosystems indicating different combinations of TFA with scavengers, as well as
information on which protective groups are ideal for the various amino acids, was used
when planning the synthesis of different peptides.202 Amino acids can be purchased with
different permanent and temporary protective groups, and although the temporary
protective groups used in this work was always fmoc,203 literature is available to
determine which protective groups are ideal for various syntheses.204 The cleavage
reaction took place at RT for 3 to 6 h. The workup following chemical cleavage involved
washing away the cleavage cocktail with cold diethyl ether. The liquid contents were
drained into 50 mL Falcon® tubes containing diethyl ether that was chilled in the -20 °C
freezer during the length of the cleavage reaction.
Note that this workup pertains to SPPS reactions with RINK Amide AM resins only and
the work up with Tentagel resins is explained in Section 2.8.2. With the peptide present
in the cold diethyl ether, the tubes were balanced, vortexed, and centrifuged at 8,000
RPM at 4 °C for 6 min which forced the peptide into a tight pellet at the bottom of the
tube. The diethyl ether was then drained and replaced with fresh cold diethyl ether. The
pellet was disturbed by vortexing to allow thorough washing with the diethyl ether. This
process was repeated two additional times for a total of three cold diethyl ether washes.
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A minimal amount of ddH2O with 0.1% TFA was added to dissolve the peptide pellet,
and purification (HPLC) and subsequent lyophilization produced the peptide as a white
powder.

Figure 2.3: General schematic of solid-phase peptide synthesis. SPPS involves the
addition of individual amino acids with side chains protected with temporary protective
groups (blue triangles) and permanent protective groups (red triangles), when
necessary, in an orthogonal fashion. After completion of amino-acid coupling, treatment
with the trifluoroacetic acid cocktail removes the solid support (grey - for amidated
peptides discussed in this work) and all permanent protective groups (red triangles)
yielding the final product.
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Quantification of the peptide took place by concentrating pure isolated stocks from
HPLC purification into a pre-weighed, autoclaved, 1.7 mL Eppendorf tube of which a
final mass would determine how much peptide was available for experiments. In
addition,

the

concentration

was

verified

using

a

Beckman

Coulter

DU800

spectrophotometer at wavelength 205 nm. Samples were read in triplicate and
absorbances averaged prior to using Beer's law for concentration determination.205
MALDI-TOF MS was used to characterize the peptides for size and purity (Section
2.3.2).
2.2.5

Kaiser test used to monitor SPPS progress

A hot water bath was produced using a 100 mL beaker filled with approximately 75 mL
of ddH2O and a hot plate. A small amount of beads were removed from the SPPS vessel
and placed in a 12 x 75 mm Pyrex test tube. The beads were washed three times at 10x
resin volume with DMF, DCM, and diethyl ether carefully in order leave the beads in the
tube. The solvent was removed with a glass pipet and the Kaiser test reagents were
added in the following order using solutions previously prepared and stored in 50 mL
squeeze bottles capable of being dispensed one drop at a time: 4 drops of solution A
(ninhydrin 5% w/v in EtOH), 2 drops of solution B (phenol 4:1 w/v in EtOH), and 2 drops
of solution C (2% v/v of 1 mmol/L aqueous solution in pyridine). The tube was left in the
hot water bath for 5 min and removed using forceps. Beads were then observed for
reaction progression. Blue or purple beads indicated incomplete coupling or successful
deprotection and clear beads indicated complete coupling or unsuccessful deprotection.
2.2.6 Purification of synthesized peptides
Purification of peptides was done using high performance liquid chromatography
(HPLC). This system efficiently separates peptide products with a reverse-phase liquid
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chromatography column. In this case, a Phenomenox® C18 Luna Column with the
following specifications - C18, 10.00 x 250 mm, 5 μm, 100 Å - was used for all
purifications. In order to determine the column volume (CV), the following formula was
used: C18: π(52)(250) = 19.6 mL/CV. With a flow rate of 5 mL/min, it would take 4 min to
attain one CV. A Waters HPLC 600 controller with 2996 detector and autosampler was
used to complete this experimentation. There were four lines available and utilized for
purification. Line A contained ddH2O + 0.1% TFA (1 mL TFA/1000 mL solvent). Line B
contained HPLC-grade ACN + 0.08% TFA (0.8 mL TFA/1000 mL solvent). Line C
contained only ddH2O, and line D contained only HPLC-grade ACN. All solvents were
degassed for a minimum of 1 h. The sparge rate for pre-degassing was 50 mL/min and
was maintained throughout the experiment. The program design was based on running
a minimum of 3 CVs of solvent at each phase.
Over the course of 85 min, 3 CVs of ddH2O + 0.1% TFA was followed by a 0-30%
acetonitrile + 0.08% TFA gradient solvent system over the course of 3 CVs. For an
additional 3 CVs, a 30% acetonitrile gradient was maintained because products with
permanent protective groups, particularly those with aromatic functionalities, elute off the
column at this percentage. The column was then returned to its pre-equilibrium condition
over the course of 3 CVs in order to prepare the column for another peptide injection.
The program design for purification would sometimes vary depending on the complexity
of the peptide, but all purification was based on the following program design which
lasted 1.4 h per run. A blank run prior to each purification took place in order to assure
that most if not all crude sample was removed to prevent contamination of the next
sample to be purified.
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To prep the C18 column for peptide purification and to remove any crude materials
that might still be in the column from previous experiments, an equilibration program was
utilized with 3 CVs of pure ddH2O followed by 3 CVs of 0-100% ACN. The ACN, 100%,
was maintained for 3 CVs before returning to pure ddH2O, 0% acetonitrile, over the
course of 3 CVs of which this gradient was maintained for an additional 3 CVs. The final
equilibration step involved introducing ddH2O + 0.08% TFA over the course of 3 CVs
and this gradient was maintained until peptide purification took place.
Completion of peptide purification would lead to several 2.0 mL autoclaved Eppendorf
tubes containing purified samples within an ACN/ddH2O solvent. These samples were
dried using the speed vac or lyophilizer depending on the amount of material to be dried.
Analysis using MALDI-TOF MS (Section 2.3) was used to determine purity and
determination of correctly isolated product prior to conducting any experiments with the
peptide.
2.3

Matrix assisted laser desorption ionization time of flight mass spectrometry

(MALDI-TOF MS)
2.3.1

Introduction to MALDI-TOF MS instrumentation

Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDITOF MS) is a soft ionization technique capable of producing singly charged ions of
macromolecules. Like all mass spectrometers, the MALDI-TOF instrumentation contains
an ion source used to ionize and transfer sample ions into the gas phase. In addition, a
mass analyzer is used to separate these ions according to their individual mass-tocharge (m/z) ratio and a detector is present to monitor the separate ionized sample ions.
MALDI-TOF MS typically requires samples to be prepared with a matrix, which is
composed of acid molecules that have strong optical absorption in the range of the laser
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wavelength used in the instrumentation. Figure 2.4 gives an illustration of how a typical
MALDI-TOF mass spectrometer works.

Figure 2.4 Adaptation of MALDI-TOF MS Instrumentation.206 The sample is mixed
with the matrix and crystallized on a metal plate. The metal plate is inserted into the
instrument and bombarded with laser pulses. The pulses cause desorption and
ionization of the sample, which is then accelerated into an electrostatic field allowing for
ejection through a metal flight tube under vacuum. While in this tube, sample ions are
separated by mass with smaller ions traveling faster than large ions into the detector.
The detector divides ions according to their time-of-flight (TOF), which creates a mass
spectrum containing analyte information by their mass-to-charge ratio (m/z) in the form
of peaks with varying intensities.
2.3.2

Materials and method for MALDI-TOF MS instrumentation in peptide

studies
The matrix used for all peptide analysis was α-cyano-4-hydroxycinnamic acid
purchased from Sigma-Aldrich (St. Louis, MO). Matrix was freshly prepared by adding a
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saturating amount of the yellow powder into a 1.7 mL autoclaved Eppendorf tube
containing a 1:1 mixture of ddH2O in 0.1% TFA and ACN (Vf = 500 μL). Samples are
prepared on a MALDI-TOF metal target plate by taking 2 μL of sample into a 0.5 mL
polypropylene tube of which 2 μL of freshly prepared matrix is added. Contents were
pipetted up and down to homogenize the sample with the matrix and then immediately
spotted onto two allocated spots (2 μL each) on the MALDI-TOF metal plate. Samples
were left to crystallize on the plate prior to insertion of the target into the instrument.
Three calibration standards were used to ensure accuracy of mass information collected
from each sample. The standards were purchased from Sigma-Aldrich were angiotensin
I (1296.48 g/mol), angiotensin II (1046.18 g/mol), and bradykinin fragment 1-5 (572.66
g/mol). Peptides in this work were analyzed in the positive-ion reflectron mode with a
mass range of approximately 500 Da (mass higher than the matrix) to at least double the
mass of the anticipated mass of the peptide analyzed. This range would account for the
presence of possible peptide dimers and crude versions of the peptide.
The MALDI-TOF instrument used for peptide analysis was a Bruker Ultraflex (Bruker
Daltonics, Billerica, MA) with a 384-well sample plate, reflectron and PSD fragmentation
capability located in the Lumigen Instrumentation Center, Department of Chemistry,
Wayne State University. The instrument was capable of resolving isotopes for species in
the 5000 Da range and had a demonstrated useful mass range from 10 to approximately
150,000 Da. Positive and negative ion modes were installed and automated acquisition
of 384 samples were possible. The instrumentation was made available for walk-up use
by trained users. Since the completion of this work, the instrument described has been
replaced with an updated version from the same company.
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2.4

RNAs used in this work

2.4.1

Synthetic RNA

Unmodified H69 (H69UUU) RNA with the sequence 5'-GGCCGUAACUAUAACGGUC3' (ε, 189,400 L/(mol*cm)), modified H69 (H69ΨΨΨ) with the sequence 5'GGCCGΨAACΨAΨAACGGUC-3' (ε, 187,000 L/(mol*cm)), and 5'-biotinylated modified
H69 (5'-Bi-H69ΨΨΨ) with the sequence 5'-Biotin-GGCCGΨAACΨAΨAACGGUC-3' (ε,
187,000 L/(mol*cm)) as well as 5'-biotinylated unmodified H69 (5'-Bi-H69UUU) with the
sequence 5'-Biotin-GGCCGUAACUAUAACGGUC-3' (ε, 189,400 L/(mol*cm)), was
purchased from Dharmacon (Lafayette, CO).207 RNA was purchased with 2'-deprotection
and desalted. An additional ethanol precipitation with ammonium acetate was
performed. Samples were washed in 70% ethanol and dried. Pellets were dissolved in
minimum amounts of double deionized water (ddH2O), pH 7.0. Concentration
determination was achieved by producing a diluted sample from the concentrated stock
and obtaining the absorbance on a Beckman Coulter DU800 spectrophotometer
(Beckman Coulter, Brea, CA) at 260 nm.
2.4.2

Transcribed RNA – materials

RNA transcription was also performed to produce H69UUU. The DNA template and T7
promoter was purchased from Integrated DNA Technologies (Coralville, IA). The
H69UUU

template

sequence

used

for

transcription

is

5'-

GACCGTTATAGTTACGGCCTATAGT GAGTCGTATTA-3' (ε, 359, 200 L/(mol*cm). The
H69 T7 promoter sequence is 5'-TAATAC GACTCCTATAGG-3' (ε, 192, 600 L/(mol*cm).
Transcription buffer (10x stock): 38 mM spermidine (Sigma-Aldrich, St. Louis, MO),
101 mM dithiothreitol (DTT) (Fisher Scientific, Pittsburgh, PA), and 800 mM Tris-HCl, pH
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8.0 (Fisher Scientific, Pittsburgh, PA). The nucleotide triphosphates (NTPs), ATP, CTP,
GTP, UTP, and GMP, were purchased from Sigma-Aldrich (St. Louis, MO).
2.4.3

Transcribed RNA – T7 RNA polymerase in vitro transcription

To perform transcription, the working concentration for the template and primer DNA
was 0.4 μM and 32 mM Mg2+. A 4x stock of NTPs with GMP, a 16 mM stock solution (4
mM of each NTP) was produced. For a 1 mL reaction, 100 μL of 10x transcription buffer,
200 μL of PEG 8000 (40%), 250 μL of 16 mM NTPs (+GMP) solution, 32 μL of 1 M
MgCl2, DNA template and primer with a final concentration of 0.4 μM, and ddH2O was
added up to 1 mL final volume. One hundred μL of T7 polymerase was added last. The
reaction was placed in a 37 °C water bath for 3-5 h. Once the reaction was complete, the
tube was centrifuged to remove the magnesium pyrophosphate precipitate. An ethanol
precipitation with sodium acetate (NaOAc) (1 volume (V) of supernatant to 3 V of cold
EtOH and 0.1 V of 3 M NaOAc) was performed on the supernatant of the transcription
reaction. The precipitate, which contains the transcribed RNA, was dried in the speed
vac. The sample was redissolved in loading buffer (9 M urea, 100 mM EDTA) prior to
loading onto a 20% polyacrylamide denaturing gel (15 cm length x 20 cm wide, 2 mm gel
thickness, 700 V, 1x TBE buffer, overnight).
The gel was placed on a fluorescent TLC plate and RNA bands were visualized using
UV shadowing from a hand-held UV lamp (254 nm). The bands were excised and
underwent crush and soak conditions (350 mM NaOAc, pH 5.3, 0.1 M EDTA 4°C,
vertical spinner, overnight). The supernatant was desalted using a Sep-pak column
(Waters). RNA underwent CIP (alkaline phosphatase, calf intestinal, New England
Biolabs, Ipswich, MA) digestion to remove the 5' phosphate of full-length RNA, which
makes the transcribed product identical to its synthesized counterpart used in similar
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work. Another 20% polyacrylamide gel and subsequent crush and soak and desalting
step was repeated to attain purified transcribed RNA for experimental use.
2.5

Circular dichroism

2.5.1

Introduction to circular dichroism

Circular dichroism (CD) is based on the differential absorption of circularly polarized
components of plane-polarized radiation.208 Results that are obtained using CD depend
on the structures of the samples, therefore their ability to interact differently with rightand left-handed polarized light provides global structural information. For a CD signal to
be obtained, the sample being analyzed must be chiral. In addition to chirality,
conformation is of extreme importance, as secondary structure information of both
proteins and nucleic acids is often sought out. Different conformations, such as α helices
and β sheets in proteins or A form and B form in nucleic acids, have unique CD profiles
that can be used to analyze unknown or novel biomolecules.
Compounds with similar structural components, such as secondary structure motifs,
often demonstrate spectral similarities in CD, thus allowing for global trends to be
identified.209 Differences in CD spectra can be used to determine global conformational
changes amongst related biological molecules or during binding events.209 When
different ligands are bound to a chiral target, changes in the CD spectra relative to the
individual, unbound target spectrum can often be observed, yielding evidence that a
binding event with a corresponding change in target conformation has occurred.
Experiments using CD are of particular importance when high-resolution experiments
cannot be performed due to increased sample requirements. It is also of great use when
trying to determine whether high-resolution experiments should be performed if target or
ligand sample amounts are limited.
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To process data obtained using CD instrumentation, several equations must be utilized
to convert raw data to a format that can be understood and compared against.208-211
During the course of experimentation, unpolarized light information is obtained and is
associated with reported absorbance, A, values, given that the log of the intensity of the
incident light, I0, is divided by the intensity, I, after the light has traveled through the
distance of the medium, as shown in Equation 2.1:
Equation 2.1:

=

Using the Beer-Lambert law, Equation 2.2, the distance of the medium, l, is taken into
direct correlation with the sample concentration and the molar extinction coefficient.
Equation 2.2:

=

The change in molar extinction coefficients is further derived based on data correlating
to the right-handed circular polarized light, rcpl, and left-handed circularly polarized light,
lcpl. The molar extinction coefficients for the lcpl and rcpl are denoted as εL and εR,
respectively, in Equation 2.3, as it is shown extrapolated from the Beer-Lambert
Equation 2.2.
Equation 2.3: ∆

=

−

=(

−

/ )

In the case of Equation 2.3, the molar circular dichroism, Δε, is defined by the difference
between εL and εR as shown in Equation 2.4.
Equation 2.4: ε = (εL + εR)/2
Werner Kuhn further described the anisotropy factor, also known as the dissymmetry
factor, to address how difficult it is to measure the CD in the region of any given
absorption band.212 The dissymmetry factor is the ratio of the molar circular dichroism,
Δε, divided by the molar extinction coefficient, ε, of the unpolarized light (Equation 2.4)
as shown in Equation 2.5.
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Equation 2.5:

∆

=

(

(

)

)

The dissymmetry factor is significant because it addresses the signal, in this case Δε, to
noise, ε, ratio. The range for the dissymmetry factor is most commonly found around 10-4
and rarely exceeds 10-2.
Most CD instrumentation today addresses the molar circular dichroism, Δε, in terms of
molar ellipticity, θ, which is the angular measurement relative to ΔA = AL – AR as shown
in Equation 2.6 and its unit is cm2/dmol.208 The molar ellipticity, θ, is more often than not
reported over Δε in biochemistry based literature.208
Equation 2.6: θ = 32.98ΔA
Molar ellipticity eliminates the contributions given by the pathlength and concentration
as shown in Equation 2.7.208
Equation 2.7: [θ] = 100θ/lc = 3298Δε
2.5.2

Circular dichroism for peptides

As described in the previous section, generalized information regarding secondary
structure can be determined using circular dichroism. In the case of peptides, three
types of secondary structure, α helix, β sheet, and random coil can be identified by using
circular dichroism.
The α-helix secondary structure of peptides and proteins is characterized by three CD
peaks, one positive (π-π*) from 190-195 nm, and two negative shown at 208 nm (π-π*)
and 222 nm (n-π*), respectively. The β-sheet secondary structure produces one positive
peak (π-π*) at 195-200 nm and one negative peak that ranges from 215 to 220 nm.
Peptides without an α-helix or β-sheet secondary structure, known as a random coil,
tend to have a negative peak at 200 nm (π-π*) and positive peak at 220 nm (n-π*). The
peaks associated with each secondary structure are illustrated in Figure 2.5.213
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Figure 2.5: Circular dichroism representation of peptide secondary structure. This
figure is an adaptation of typical peptide secondary structure data associated with
circular dichroism experimentation.213
2.5.3

CD instrumentation and materials

Potassium chloride and sodium cacodylate were purchased from Fisher (Waltham,
MA). Cacodylate buffer components: 100 mM potassium chloride, 5 mM magnesium
chloride, 10 mM sodium cacodylate, pH 7.0. A Chirascan CD spectrophotometer
(Applied Photophysics, Leatherhead, United Kingdom), located in the RNA instrument
room in the Department of Chemistry, Wayne State University, was used to perform all
CD experiments. The Chirascan CD spectrophotometer was flushed with N2 gas for 3 h
prior to warming up the lamp. The lamp warmed up for 1 h prior to use. The wavelength
range used for binding experiments was 180 to 320 nm to account for peptide and
nucleic acid ranges. A run with buffer only was used to get a background reading and
subtracted from each sample. Three complete scans of each sample run in duplicate
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was done to assure consistent in data collection. Data were exported into a Microsoft
Excel file which was used to process the data and create graphical figures.
2.5.4

Protocol for circular dichroism spectroscopy of peptides

To perform binding studies with amidated peptides and RNA, a 10х stock of CD buffer
containing 10 mM potassium phosphate buffer, pH 7.0, and 100 mM potassium fluoride
was produced. Individual peptides were incubated with 25 μM of renatured RNA.
Samples with a final volume of 220 μL were placed in a quartz cuvette and data
collection took place on a Chirascan CD spectrophotometer. Prepared samples were
lightly mixed and incubated at 37 °C for 15 min. Samples were stored on ice until data
collection took place. All experiments were performed in duplicate with three complete
scans of each sample.
2.6

Isothermal titration calorimetry (ITC)

2.6.1

Introduction to isothermal titration calorimetry

Of the biophysical chemistry techniques available, isothermal titration calorimetry (ITC)
is a direct, highly accurate form of measurement of the heat that generated or absorbed
when two molecules interact with one another.214-215 This technique offers data with
biological relevance because samples do not require labels and are not restricted by
their molecular weights or optical clarity. Results obtained from this instrumentation are
highly accurate and absolute dissociation constants (Kd) can be determined.214-215 The
only major limitation with this technique is the requirement for a large amount of material;
however, the material can be recovered in the absence of protease/nuclease activity.
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2.6.2

Isothermal titration calorimetry instrumentation

The VP-ITC MicroCalorimeter (MicroCal™) (Northhampton, MA) was used for all
experiments discussed in this report. An electronic feedback circuit is what makes ITC
possible.214 It controls the heating elements that surround the reference and sample
cells. When titrant, located in a specialized syringe with rotating spinner, is added to the
titrate, located in the sample cell, the energy is monitored in order to maintain constant
temperature of the reference and sample cells. This provides information regarding heat
or energy, depending on the instrumentation, associated with each point of the titration.
From this information the binding enthalpy can be determined when the cell volume and
reactant(s) concentration is known. Figure 2.6 shows a schematic diagram of the ITC
instrumentation.
Figure 2.6 Schematic diagram of
isothermal
calorimetry
calibration.214-215 This figure was
adapted from a review written by Dr.
Andrew Feig.215 Heat is monitored
within
the
adiabatic
jacket
surrounding
the
sample
and
reference cells. As titrant is
incrementally added, the stir bar
constantly mixing the titrate, and final
solution, absorbs or gives off heat.
This causes changes in heat
produced by the electronic feedback
circuit in efforts to maintain
temperature. When an energy
change occurs, the change in
temperature can be monitored giving
thermodynamic information regarding
the combination of the two samples.
Depending on the instrumentation
available, heat can be measured
either by the change of temperature
or the change in energy. The energy identified by the instrumentation is converted into a
binding enthalpy and can be interpreted if the cell volume and the concentration of the
reactants are known.
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2.6.3

Protocol of isothermal titration calorimetry

A Microcal Inc. ITC instrument (Northampton, MA) was used to complete all
experiments. The experiments were conducted as previously described.216 Very briefly,
the sample cell was passivated with 1 L filtered ddH2O, pH 7.2, followed by 1 L of 1x
phosphate buffer A (10 mM potassium phosphate, 100 mM KCl, pH 7.2) or 1 L of 1x
phosphate buffer B and the reference cell was filled with degassed water. The RNA and
peptide were previously purified using the HPLC, was dried and re-suspended in 1x
phosphate buffer (A or B). The RNA was renatured prior to all experimentation. RNA and
peptide samples were degassed in a Thermovac (Northhampton, MA) at 25 °C for 8 min
prior to loading the sample cell and syringe. The experiment was carried out at 25 °C. A
typical experiment would have 18-25 injections (10 μL) with a duration of 30 s, and a
spacing at 300 s per injection. The reference power was maintained at 29 μcal/sec. The
concentrations of the RNA and peptide varied dependent on the experiment. Details can
be found in Chapter 4 of this work.
2.6.4

Isothermal titration calorimetry data analysis

Data analysis involves consideration of several parameters utilized during the
experimentation. When data are obtained, the information is systematically processed
using ORIGIN software (MicroCal Inc., version 7.0, Northhampton, MA)). The software
normalizes the heat of binding relative to the ligand concentration. Based on the data
collected, systematic processing sets the baseline, performs a volume correction based
on the dilution of the titrate during each injection, and integrates each peak from the
baseline before the binding model is selected for final processing. Results obtained from
the initial analysis can give information regarding dissociation constants, thermodynamic
profiles, and can also be used to troubleshoot experimental problems such as buffer
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mismatch and nuclease contamination.214-215 Results were exported as an ASCII file and
figures were created using Microsoft Excel.
One of the first parameters to address when data are obtained is how to remove
irrelevant data pertaining to background heats. Since the observed enthalpy (ΔHobs) is a
collective measurement of all heat sources within the sample cell, information will
include binding data as well as background.214-215 There are two accepted methods
utilized to remove background thermodynamic information, each with pros and cons to
using them.214-215 The first would be to incorporate additional injections to the overall
experiment in order to reach a saturation of the titrate and titrant. This information is then
subtracted from the experimental run saving material and time. The limitation with this
method is that the material used in the experimentation may undergo differences in their
thermodynamic profile, which would then be construed as a result for the overall
experiment. The second accepted method is to run a background heat omitting the
titrate and injecting titrant into the buffer only. Although this method takes additional time
and material, the material may be recovered for future experiments as long as
degradation or contamination does not occur. In addition, if the titrate underwent any
aggregate binding, evidence of this would be observed in the results. For the purpose of
all experimentation associated with this work, the latter method was utilized to first
observe titrant (peptide) behavior since ESI MS data did show greater than 1:1 binding
stoichiometry for some H69 peptides. The peptide was recovered and re-purified to omit
excess salts present in the buffer from interfering with future runs.
The integrated data from the experiment are derived from deflections from the baseline
as a result of a change in differential power required to maintain the sample and the
reference cell at the same temperature and integrations of each peak is associated with
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the heat of each injection (qi).214 Mapping of each integrated peak provides the fractional
saturation of the binding reaction (F) based on the stoichiometry (n), the total
concentration of the titrate (MT), the binding enthalpy (ΔH) and the cell volume (V), when
the concentration of the titrant (BT) is known as shown in Equations 2.8 through 2.10.214215, 217-218
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The solution obtained from Equations 2.8 through 2.10 can be applied into a nonlinear least squares analysis to solve for the enthalpy (ΔH), the binding constant of the
reaction (KB), stoichiometry (n), where KB is used to determine Gibbs free energy (ΔG)
(Equation 2.11) and entropy (ΔS, Equation 2.12).214-215, 217-218
Equation 2.11:

-H = −IJK=(L3 )

Equation 2.12:

-H = -. − J-M

2.7

Electrospray ionization mass spectrometry (ESI MS)

2.7.1

Introduction to electrospray ionization mass spectrometry

Electrospray ionization is a process that converts solutes present in a solution into
gas-phase ions that can be identified.219-220 This instrumentation can handle a wide array
of sample types ranging from small compounds to large proteins and nucleic acids. The
solution contains electrolyte ions that are converted into charged droplets at the heated
electrospray capillary tip. These charged droplets are further consolidated by solvent
evaporation, and repeated droplet disintegration forces the charged droplets into gasphase ions.221
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In order to convert solution-phase ions into gas-phase ions, the solution needs volatile
solvents such as methanol, ethanol, isopropanol, or acetonitrile incorporated into the
sample preparation. Titrations of the sample material (ligand) to be tested for target
interactions can provide important binding information. In situations involving equal
ionization amongst all components in the sample, dissociation constants can be easily
determined.222 In cases in which ionization of the samples is not equal, relative
intensities of all charged species can be used to determine relative dissociation
constants as is the case with peptide-RNA binding studies that will be described in
Chapter 3.
2.7.2

ESI MS materials, instrumentation, and method

Binding studies were performed on a Micromass QuattroLC triple quadrupole mass
spectrometer with an electrospray/APCI source and Waters Alliance 2695 LC,
autosampler and photodiode array UV detector (Manchester, UK). This instrument was
used to analyze polar and high molecular weight compounds ranging from under 100 Da
to proteins over 80 kDa. The m/z range covers 2 to 4000 Da, but higher MW species can
be measured since they take on multiple charges. The QuattroLC has an accurate mass
option, which allows acquisition of mass data at low resolution (0.15 Da, 128 points/Da)
but high accuracy (within 5 ppm). This instrument was available to trained users;
however, is no longer available for use following the work described due to permanent
disrepair.
Peptides (0 – 120 µM), previously synthesized and purified (Section 2.2), were titrated
with renatured synthetic H69 RNAs, Section 2.4, (2.7 - 3 µM) in 50% isopropanol
(Sigma-Aldrich, St. Louis, MO) in ddH2O and ammonium acetate (Sigma-Aldrich, St.
Louis, MO) (Cf = 150 mM) and incubated for 15 min at room temperature prior to
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infusion. The spectrum of the infused sample was obtained for the mass-to-charge ratio
(m/z) range of 1100–2400 to reveal complexes of RNA and peptide, as well as free
RNA, in the (3-), (4-), and (5-) charge states. Note that complex formation in the (3-)
charge state was never observed so information from the (3-) charge state (free RNA)
was not included in the analysis. These values were used to calculate the relative
dissociation constant, Kd, of the peptide to RNA. The sample (50 – 100 µL) was infused
with a Hamilton® 100 µL glass syringe at a rate of 6 µL/min. A cone voltage of 40 for
H69ΨΨΨ and H69UUU and 50 for 5'-Bi-H69ΨΨΨ and 5'-Bi-H69UUU RNA was
maintained, and the spectra were analyzed with the Mass Lynx® V. 4.0 processor
program (Waters, Milford, MA).
2.7.3

Data analysis of ESI MS

Results were obtained using Mass Lynx® software V. 4.0 (Waters, Milford, MA).
Smoothing took place for each experiment by selecting the spectrum associated with an
RNA-only run (in absence of peptide). The peak associated with the (4-) charge state of
H69 RNA was selected and expanded due to its consistent and dominant presence
throughout all ESI MS experimentation with H69 RNAs and selected peptides. The value
associated with the peak width at 50% of the peak height was inserted into the SatviskyGolay algorithm.223 The result for the algorithm was then applied toward smoothing the
rest of the spectra associated with the experiment. The relative fraction bound of RNA
(Fr) involved taking the peak intensities associated with the (4-) and (5-) charge states of
the RNA-peptide complex and dividing those values by the total intensities associated
with the binding complex, as well as free RNA, at the (4-) and (5-) charge states. Peaks
correlating to salt adducts associated with the binding complex, as well as free RNA, are
included in this calculation. It is assumed that the peak area is proportional to the
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concentration of the RNA in solution, and the dissociation constant for each peptide with
H69 RNAs was obtained by plotting Fr vs. [peptide, μM] using a non-linear curve fitting
with the quadratic equation (Equation 2.13).222,

224

Plotting of data took place on

Kaleidograph (version 4.0) software. Equation 2.13 correlates data obtained from free
RNA (R) relative to the RNA-peptide complex (RP). Peptide (P) is further seen in the
quadratic portion of this equation.
Equation 2.13:

NOP
NQ NQR

=

V

([O]S [P]S 8T ) (([O]S [P]S 8T )U B[O]S [P]S )U
1[O]S

2.8

RNA-peptide fluorescence screening assay

2.8.1

Introduction to the RNA-peptide fluorescence screening assay

Screening peptides with ESI MS has yielded helpful information regarding the
selectivity and affinity of modified heptamers to target RNA; however, the process of
attaining this information was very time consuming in terms of both the synthesis and
purification of individual peptides needed to perform the experiments. In many cases the
peptides screened for dissociation constant determination consumes large amounts of
peptide and RNA only to find that they are not better binders to the target RNA. It also
requires a lot of RNA and peptide that cannot be recovered and re-used. This challenge
has established a need for an assay that can screen libraries of peptide versus individual
peptides. High-affinity peptides identified from a library-screening assay can then be
synthesized, purified, and tested for selectivity and affinity can be confirmed. To address
this challenge, a visual assay using quantum dots (Qdot) as fluorophores, flow cytometry
as the method to screen hits, and mass spectrometry to identify the screened hits was
developed. Identified peptides can then undergo binding studies with RNA to determine
the relative affinity and selectivity.
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2.8.2

Materials for the visual screening assay and SPPS protocol method

modifications
Materials used in this assay include 1x PBS buffer (freshly produced from a 10x stock:
137 M sodium chloride (Fisher Scientific, Pittsburgh, PA), 2.7 mM potassium chloride
(Sigma-Aldrich, St. Louis, MO), 100 mM sodium phosphate (Fisher Scientific, Pittsburgh,
PA), and 18 mM potassium phosphate (Fisher Scientific, Pittsburgh, PA)). Qdot 605 with
streptavidin conjugate was purchased from Life Technologies (Grand Island, NY). 5'-BiH69ΨΨΨ RNA was purchased and prepared as described in Section 2.4.1. The 3amino-3-(2-nitrophenyl)propionic acid (ANP) was purchased from Advanced Chemtech
(Louisville, KY).
To test the overall design of this assay, H69 peptides with modifications in position one
were tested. The rationale is that ESI MS data determined that position one
modifications yielded both high and low affinity H69 peptides. Based on these findings, it
is likely that other peptides with modifications at position one will also bind to the target
H69, which would help test the validity of the assay. In order to first be able to identify
the individual peptides and test for assay success, seven position 1 peptide variants
along with individual peptides designed to serve as controls were produced as described
in Section 2.2.4; however, the workup following the completion of the synthesis was
modified to attain the product necessary for this work. Since the assay required the
peptide to remain on the bead, Tentagel bead resin was used for this work. In order to
identify the peptide post-screening, a photocleavable linker was incorporated during the
synthesis to allow release of the peptide for later identification. Care was taken to protect
the product from light exposure by wrapping the synthesis vessel in foil once the ANP
linker was added to the resin.
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In efforts to be sure that each bead containing peptide has adequate access to the
biotinylated RNA and subsequent streptavidin-coated Qdot solution, an additional
KGGGGG linker was added followed by 3-amino-3-(2-nitrophenyl)propionic acid (ANP, a
linker cleavable by UV light). The lysine, a positively charged amino acid, would repel
other lysines on the bead, which was designed to help prevent aggregation of the
peptides on a single bead. This motif along with a 5-glycine and ANP linker helped
enable individual peptide access the target RNA. The ANP linker was incorporated for
easy release of the peptide for later identification as cleavage produces an amidated Cterminus of the desired peptide.225
Since the solid support is not cleaved using the chemicals described in Section 2.2.4,
peptides used in this project were washed several times with cold diethyl ether with
water vacuum and shaking while still in the synthesis vessel. They were then washed
with 1:1 ACN in ddH2O ten times at 10x resin volume followed by ddH2O, pH 7.2, ten
times at 10x resin volume before being dried and stored at -20 °C in 1.7 mL autoclaved
Eppendorf tubes wrapped in foil. The seven position 1 peptides were produced in a splitpool manner and differ from one another by mass and can be identified using MALDITOF MS (Section 2.3.2). Note that identifying peptides in pools containing six at a time
is not considered efficient, but this approach was used for the purpose of assay design
and testing, with the future goal of expanding to larger libraries. Table 2.1 represents all
of the peptide sequences synthesized for this work. The peptides and the corresponding
expected masses after UV cleavage.
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Table 2.1 Peptides synthesized for the visual assay
Chemical
Monoisotopic
Peptide
Formula
Mass (g/mol)
NQVANHQ-NH2
C32H52N14O11
808.39
AAAAAAA-NH2
C21H38N8O7
514.29
RQVANHQ-NH2

C34H58N16O10

850.45

DQVANHQ-NH2
MQVANHQ-NH2
FQVANHQ-NH2
GQVANHQ-NH2
PQVANHQ-NH2
SQVANHQ-NH2

C32H51N13O12
C33H55N13O10S1
C37H55N13O10
C30H49N13O10
C30H53N13O10
C31H51N13O11

809.38
825.39
841.42
751.37
755.40
781.38

Role in visual
assay
positive control
negative control
ESI MS selected,
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant

Although the exact parameters for the completion of this assay were not directly from
one piece of literature, the bead assay with Qdot usage was adapted from work
previously

reported

Udugamasooriya.188,

by

195, 226-227

Tom

Kodadek,

Webster

Santos,

and

Gomika

Their work primarily used fluorescence microscopes for

detection, whereas the work discussed in this document uses flow cytometry. Results
from this experimentation were attained using the Microscopy, Imaging and Cytometry
Resources Core at Wayne State University, School of Medicine. This service was
performed by Eric Van Buren, flow cytometry core manager, using a SH800 cell sorter
(model LE-SH800ZFP, Sony Biotechnology, Tokyo, Japan). A violet laser (405 nm) was
used to excite Qdot605 and a 600/60 bandpass filter (570-630 nm) was used to capture
its fluorescence. Forward scatter (FSC) and back scatter (BSC) were generated from a
blue laser (488 nm). The blue laser was also used to monitor autofluorescence (AF)
using a 525/50 bandpass filter. A 100 μm sorting chip was used to flow samples through
for detection and beads that held high fluorescent activity were sorted individually in a 96
well plate. Low-speed, low-pressure sorting conditions were used (20 psi sheath
pressure, 26 kHz drop drive frequency).
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2.8.3

Instrumentation for the visual screening assay - introduction to flow

cytometry
Flow cytometry is instrumentation that is capable of measuring and analyzing the
samples relative size, granularity, and relative fluorescence intensity simultaneously.228229

The detector records how the sample, whether it's a cell, particle, or bead in this

case, scatters incident laser light, which in turn emits fluorescence. A flow cytometer is
composed of three essential systems.228-229 The first is fluidics, which is normally the
buffer, or sheath fluid, which transports samples through the instrumentation in singlelined format.228-229 The second system, optics, consists of lasers needed to illuminate the
sample from the fluidic stream.228-229 Optical filters are also utilized in conjunction with
fluorescently labeled samples to transmit detected signals to the appropriate
detectors.228-229 The final system, electronics, takes the detected light signals from the
optical filters and converts them into electronic signals, which are then processed
computationally.228-229 Figure 2.7 shows a schematic representation of the flow
cytometry instrumentation.
Figure 2.7: Flow cytometry
scheme.230 The sheath fluid,
system
fluidics,
shuttles
samples individually pass the
laser source, system optics,
of which the laser in
conjunction with fluorescence
filters,
provides
physical
information regarding the
sample. This information is
converted
to
electronic
signals and evaluated using
system electronics, which
provides data that can be
analyzed further.
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2.8.4

Protocol for the RNA-peptide fluorescence screening assay

The solid-support Tentagel® M NH2 microbeads were used for this work. These beads
were 10 μm dried, but when incubated in buffer can swell up to three times in size. As
long as these beads did not exceed 100 μm in size, they can successfully pass through
the flow cytometer. The flow cytometer was also accepting of the PBS buffer used
throughout the binding portion of the experiments preventing dissociation of the
fluorophore from the peptide synthesized on the solid support. In conjunction with the
swelling property of the beads, the capacity was approximately 0.2 mmol/g. For any one
bead, approximately 0.1 fmol of material was available. The seven position 1 variants as
well as individual peptides specific to this technique were prepared using 0.1-0.15 g of
solid support and the SPPS protocol described in Section 2.2.4 and work-up
modifications discussed in Section 2.8.2. After cleavage with the trifluoroacetic acid
solution containing organic scavengers, the beads still maintain their connection with the
peptide synthesized on them. The beads were thoroughly washed with cold fresh ether
to remove residual cleavage solution followed by a 50% acetonitrile solution in double
deionized water (ddH2O),

followed by thorough washes with ddH2O, pH 7.2. The

samples were lyophilized to dryness and stored at -20 °C until needed.
Peptides were incubated with biotinylated RNA at 4 °C in 1x PBS, pH 7.4 for a
minimum of 1 h on a vertical spinner. The samples were incubated with Qdot 605 with
streptavidin coating (1 μL of 1 μM stock/100 μL of PBS in sample) for 1 h on a vertical
spinner at 4 °C. Samples were wrapped in foil to prevent light from damaging the
fluorophore. After incubation, each sample was washed several times with fresh cold 1x
PBS to remove any unbound biotinylated-RNA and Qdot. The samples were then
submitted to the flow cytometry core for selection and sorting. The instrument was set to
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select for the emission wavelength of the quantum dot (Qdot) that was pre-bound to the
RNA and subsequently peptide complex.
Samples from the position 1 variants, along with NQVANHQ and RQVANHQ, were
sorted into individual wells of a 96-well plate. The plate was exposed to UV light (365
nm, 1 h) provided by a hand-held lamp allowing for peptide release from the bead
(Figure 2.8).188, 225

Figure 2.8 Tentagel peptide with ANP linker deprotection scheme. A 10 μm (dried)
Tentagel® M NH2 microbead is shown with a lysine-(glycine)5 amino acid sequence
linker followed by the photocleavable ANP linker and desired peptide for the visual assay
study. After 1 h of UV irradiation (365 nm), the ANP undergoes radical chemistry to
release the desired peptide with an amide present on the C-terminus.
The lamp was rigged to sit on top of a box containing an open slot to shine UV light
through. Inside the box was placed over the 96-well plate with samples. The plate was
lined up directly beneath the UV lamp. Post UV-cleavage, 50 μL of ddH2O was added to
each well containing sample and allowed to sit at room temperature for 20 min allowing
the peptide to be released from the plate surface. Each sample was placed in individual
0.5 mL autoclaved Eppendorf tubes (polypropylene) and dried down in the speed vac.
Samples were stored in the -20 °C freezer until mass analysis (ESI MS/MALDI-TOF MS)
could be performed. The solution from each well was analyzed using MS to determine
the molecular weight. The value obtained from mass analysis was compared to those of
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the library and the peptide was identified. Figure 2.9 shows a general scheme of the
visual screening assay.

Figure 2.9 Visual screening assay scheme. The peptide library was incubated with the
target RNA (5'-Bi-H69ΨΨΨ). After binding, excess RNA was washed away. Fluorophore
incubation using streptavidin-coated quantum dot (Qdot605) binds to the biotinylated
RNA. Excess Qdot was washed away prior to flow cytometry experimentation. Flow
cytometry detects Qdot and sorted individual beads into a 96-well plate (one bead/well).
UV light (365 nm) reacted with the linker which released the peptide. Mass spectrometry
was used to determine the mass of the peptide and identification occurred.
Samples used in the experiment along with specific parameters tested are further
discussed in Chapter 4 of this work.
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CHAPTER 3 USING ESI MS TO DETERMINE ROLES OF PEPTIDIC SIDE CHAINS IN
RNA BINDING INTERACTIONS
3.1

Introduction

Original selection experiments previously identified NQVANHQ-NH2, referred to as the
parent sequence, as a moderate binder to H69 rRNA.197 This sequence is hypothesized
to underrepresent H69 binders due to the implicated role of the target H69 in translation.
The participation of H69 in translation during the amplification stage of phage display
makes the identification of high-affinity binders unlikely. To test this hypothesis, an
alanine and arginine scan of the parent sequence was carried out with two main
objectives:
1) to determine which amino acids in specific positions of the parent sequence are
important for selective and high-affinity binding, and
2) to determine whether the introduction of a positively charged amino acid, arginine,
can enhance binding affinity to the negatively charged RNA construct.
The original selection yielded heptameric peptides, which stands to reason that not all
residues/positions are necessary for potent binding. Since there are no charged amino
acids in the original sequence, due to the properties of the phage used in the original
selection,197 a positively charged amino acid may enhance binding affinity.
The rationale behind the alanine and arginine scan is simple. Alanine is a non-bulky,
non-polar amino acid and can be used to determine which positions of the parent
sequence are important for selective binding and which positions can undergo further
modifications for enhanced affinity in addition to selectivity. Arginine is a positively
charged amino acid that may enhance affinity to the negatively charged RNA. Due to
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limitations of the original selection, peptides containing charged amino acids were not
identified, leading to the potential for enhanced binding during these modified scans.
3.2

Peptide synthesis

3.2.1

SPPS – methods

The protocol for SPPS was described in Section 2.2.4. The alanine and arginine scan
syntheses

employed

approximately

0.2-0.3

mmol

of

Rink

Amide

AM

resin

(Novabiochem, LaJolla, CA) for each peptide. Purification of each peptide was done by
HPLC according to the protocol described in Section 2.2.6, and characterization of the
purified peptides was done by using MALDI-TOF MS (Section 2.3.2).
3.2.2

SPPS – results

Fourteen peptides were synthesized as shown in Table 3.1. Figures 3.1 through 3.14
demonstrate the purity of each peptide by MALDI-TOF MS. Each figure shows a mass
range at least twice the mass of the expected peptide in order to rule out the presence of
crude peptide with incomplete deprotection as well as peptide dimer formation. An
expanded profile revealed that, in all cases, salt is present, and in most cases, an MH+ 15 mass peak (small relative to the MH+) is also present. The MH+ - 15 peak, which is
prevalent in most of the peptides shown, is likely due to de-amidation within the peptide,
either in the side chains associated with asparagine and glutamine and/or the amidated
C-terminus. Protein degradation has been identified in another work, ultimately
questioning the lifetime of synthesized proteins due to de-amidation of amidated side
chains of amino acids.231 These results are not surprising, as these peptides are very
hydrophilic and are often eluted from the HPLC column with a low acetonitrile (ACN)
gradient (0-5%) where salt is still present. Efforts were made to remove the salt, such as
injecting the original elutions for further purification or changing gradient conditions and
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solvent composition (ACN to methanol (MeOH)); however, salt was always present in
the samples. Monoisotopic and average masses were calculated for each peptide using
MassLynx V4.0 software. MALDI-TOF MS was performed as described in Section 2.3.2.
Table 3.1 summarizes the data for each peptide, including the chemical formula, the
average mass obtained from the positive-ion mode, and the observed masses (of the
most abundant species).
Table 3.1 MALDI-TOF MS predicted and observed masses for alanine and arginine
scans‡
Peptide
Chemical
Predicted
Observed Observed Observed
Formula
Avg. MH+
MH+
M + Na+
M + K+
AQVANHQ
C31H51N16O10
766.8
766.7
788.9
805.1
NAVANHQ
C30H49N13O10
752.8
752.2
774.2
790.9
NQAANHQ
C30H48N14O11
781.8
781.6a
NQVANHQ
C32H52N14O11
809.9
809.6
831.6
847.9
NQVAAHQ
C31H51N16O10
766.8
765.9
NQVANAQ
C29H50N12O11
743.8
743.4
765.5
781.5
NQVANHA
C30H49N13O10
752.8
752.4
774.4
791.3
RQVANHQ
C34H58N16O10
851.9
851.4
873.8
889.9
NRVANHQ
C33H56N16O10
837.9
837.5
859.5
NQRANHQ
C33H55N17O11
866.9
866.4
888.6
905.5
NQVRNHA
C35H59N17O11
895.0
894.7
916.3
NQVARHQ
C34H58N16O10
851.9
851.1
873.1
NQVANRQ
C32H57N15O11
827.9
827.9
849.9
NQVANHR
C33H56N16O10
837.9
837.2
‡ All of the peptides are amidated at the C-terminus
†The observed masses reported are the most abundant species except
where noted (a M-15).
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Figure 3.1 MALDI-TOF MS spectrum for AQVANHQ-NH2. A. AQVANHQ-NH2 with a
mass range of 550 – 2025 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.2 MALDI-TOF MS spectrum for NAVANHQ-NH2. A. NAVANHQ-NH2 with a
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.3 MALDI-TOF MS spectrum for NQAANHQ-NH2. A. NQAANHQ-NH2 with a
mass range of 550 – 1350 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.4 MALDI-TOF MS spectrum for NQVANHQ-NH2. A. NQVANHQ-NH2 with a
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.5 MALDI-TOF MS spectrum for NQVAAHQ-NH2. A. NQVAAHQ-NH2 with a
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.6 MALDI-TOF MS spectrum for NQVANAQ-NH2. A. NQVANAQ-NH2 with a
mass range of 525 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.

69

Figure 3.7 MALDI-TOF MS spectrum for NQVANHA-NH2. A. NQVANHA-NH2 with a
mass range of 525 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.8 MALDI-TOF MS spectrum for RQVANHQ-NH2. A. RQVANHQ-NH2 with a
mass range of 400 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.9 MALDI-TOF MS spectrum for NRVANHQ-NH2. A. NRVANHQ-NH2 with a
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.10 MALDI-TOF MS spectrum for NQRANHQ-NH2. A. NQRANHQ-NH2 with a
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.11 MALDI-TOF MS spectrum for NQVRNHQ-NH2. A. NQVRNHQ-NH2 with a
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.12 MALDI-TOF MS spectrum for NQVARHQ-NH2. A. NQVARHQ-NH2 with a
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.13 MALDI-TOF MS spectrum for NQVANRQ-NH2. A. NQVANRQ-NH2 with a
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
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Figure 3.14 MALDI-TOF MS spectrum for NQVANHR-NH2. A. NQVANHR-NH2 with a
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and
corresponding salt peaks for the peptide.
In addition to MALDI-TOF MS, the absorbance of each purified peptide stock was
checked. Impure peptides most often contain bulky aromatic groups associated with the
permanent protective groups during the synthesis. Incomplete deprotection during the
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final cleavage always left traces of these peptides in the crude form, which was
observed by MALDI-TOF MS. Since MALDI-TOF MS is not quantitative, an argument
could be made that the presence of crude material is technically possible even if it isn't
readily visualized on the mass spectrometer. To rule out this possibility, the absorbance
at 280 nm was measured. Since these peptides do not contain aromatic side chains, a
reading of zero helped confirm the purity of each one.
3.3

Binding studies of H69 peptides containing modification

3.3.1

ESI MS – method

The goal of this work was to determine the binding affinity and selectivity of
synthesized H69 modified peptides of the parent sequence in order to identify novel
tight-binding species. It was also of great importance to study the modified (H69ΨΨΨ)
and unmodified (H69UUU) H69 RNAs with these peptides in order to determine possible
binding interactions with modified nucleotides present in H69ΨΨΨ. To determine
apparent dissociation constants for each peptide, electrospray ionization mass
spectrometry (ESI MS) was performed with each peptide and H69 RNAs. The method is
described in Section 2.7.2. Previous studies demonstrated that ESI MS is useful for
determining apparent dissociation constants between RNA and ligands;197, 216 however,
note that the ionization efficiencies are not equivalent between the RNA and peptide.
This means that consideration must be taken into account when processing the data, as
the decrease of free RNA is not readily seen with increasing concentration of peptide;
therefore, dissociation constants achieved from this instrumentation are apparent or
relative and should not be assumed to be absolute. To represent this, Figure 3.15 gives
a truncated set of ESI MS spectra from a NQVANHQ-NH2 binding study with H69ΨΨΨ.
One can easily see that the ionization efficiencies are not equal and that the presence of
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peptide dimer at increasing peptide concentration also plays a role in overall ionization
efficiencies. Complete titration data for all peptide studies can be seen in Appendix A.

Figure 3.15 Truncated ESI MS spectra of a binding study with NQVANHQ-NH2 and
H69ΨΨΨ RNA. Over increasing concentrations of peptide, 1:1 binding complexes
between peptide and RNA can be visualized at the (4-) and (5-) charge states in parallel
with free RNA peaks at the same charge states. All information obtained from this data,
including salt adducts, was used to determine apparent dissociation constants.
3.3.2

ESI MS with alanine scan peptides - results

The data shown in this section revealed that modified peptides often had different
binding affinities relative to the H69 RNA (H69ΨΨΨ and H69UUU) studied. In addition,
many of these peptides had dissociation constants that differed from that of the parent,
revealing that modification to the sequence did impact selectivity. The results from the
alanine scan are represented as titration curves, in which the relative amount of bound
peptide (y-axis) is plotted against the peptide concentration (x-axis). The data were fit to
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a quadratic equation to give the apparent dissociation constant, Kd, as described in
Section 2.7.3. The data used to make these plots are given in Appendix A. Each plot
represents a minimum of two separate experiments with each titration point was done in
duplicate. Note that all peptides used in this study were amidated at the C-terminus. In
addition, note that the fraction bound values for the data shown were not normalized,
revealing that saturation was not obtained. Saturation cannot be determined because
the ionization efficiencies between RNA-peptide complex and free RNA are not equal.
More often than not, the concentration of peptide-RNA complex is very low compared to
free RNA, and although complex intensities may increase with increasing peptide
concentration, the free RNA intensities did not decrease to a measurable degree.
Increasing peptide concentration also led to the incidence of peptide dimer, which would
also affect peak intensities of the peptide-RNA complex as well as free RNA, thus
making it difficult to determine whether saturation occurred. This effect can be observed
in the data found in Appendix A.
Binding studies on the parent sequence NQVANHQ-NH2 were performed with both
H69ΨΨΨ and H69UUU RNAs in order to determine an apparent dissociation constant
for comparison to the modified alanine and arginine scan results. As shown in Figure
3.16, NQVANHQ-NH2 has an apparent dissociation constant of 4.6 μM with H69ΨΨΨ
and 23.6 μM with H69UUU. There is a 5-fold difference in binding affinity favoring the
modified H69 RNA with this peptide, which is indicative of selective binding. All data in
this chapter will be compared to the apparent dissociation constant of the parent
sequence with H69ΨΨΨ RNA, since this RNA most closely represents the wild-type
RNA. The only structural difference between the two RNAs is the presence of
pseudouridine (Ψ) in the modified construct at loop residues 1911, 1915, and 1917, as
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shown in Figure 1.10. Since the only differences between the two RNAs resides in the
loop region with the presence of modified nucleotides, the evidence supports binding to
this region of RNA.

Figure 3.16 Titration plots of ESI MS data for NQVANHQ-NH2. A. Titration plot for
NQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 23.6 ± 5.4
μM. B. Titration plot for NQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation
constant is 4.6 ± 1.7 μM.
Figure 3.17 shows the titration plot from ESI MS experiments for AQVANHQ-NH2 with
H69UUU with an apparent Kd of 9.9 μM. No binding was observed when this modified
peptide was titrated with H69ΨΨΨ RNA. AQVANHQ-NH2 was shown only to bind with
H69UUU, suggesting that position 1 with an asparagine is important for binding to the
modified H69.
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Figure 3.17 Titration plot of ESI MS data for AQVANHQ-NH2 with H69UUU. Titration
plot for AQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 9.9 ±
2.1 μM. No binding was observed with H69ΨΨΨ.
In the case of NAVANHQ-NH2, apparent dissociation constants revealed selectivity for
H69ΨΨΨ, with a Kd of 4.6 μM compared to that of H69UUU, with a Kd of 52.8 μM. The
result is shown in Figure 3.18.

Figure 3.18 Titration plots of ESI MS data for NAVANHQ-NH2. A. Titration plot for
NAVANHQ-NH2 bound to H69UUU RNA. The apparent dissociation constant is 52.8 ±
9.7 μM. B. Titration plot for NAVANHQ-NH2 bound to H69ΨΨΨ. The apparent
dissociation constant is 4.6 ± 1.8 μM.
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Figure 3.19 shows titration data for the peptide NQAANHQ-NH2, which also includes
information for 1:2 and 2:1 RNA to peptide stoichiometry. The apparent Kd for this
peptide with H69UUU is 1 μM and 5 μM with H69ΨΨΨ. Although these dissociation
constants support good affinity for their respective targets, a lack of points at lower
concentrations of peptide made it challenging to fit the data. In addition, the binding
stoichiometry also played a role in the binding constant determination, as all information
was incorporated into the calculation. The absence of valine in position 3 of this peptide
appears to increase its promiscuity in binding. The binding affinity for H69UUU has
increased when compared to the parent sequence, therefore selectivity for the modified
H69 has been compromised.

Figure 3.19 Titration plots of ESI MS data for NQAANHQ-NH2. A. Titration plot for
NQAANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 1.0 ± 0.5 μM.
B. Titration plot for NQAANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation
constant is 5.0 ± 1.0 μM.
Binding studies with NQVAAHQ-NH2 revealed no observable binding with H69ΨΨΨ
compared to an apparent Kd of 14.3 μM with H69UUU as shown in Figure 3.20. Since
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no observable binding was indicated for H69ΨΨΨ, this peptide is selective for H69UUU;
however, this dissociation constant has a value that matches closely that of the parent
sequence with H69UUU, suggesting that an asparagine to an alanine modification does
not enhance affinity nor alter its selectivity for the unmodified RNA; however, based on
this finding, it appears that position 5 is important for affinity binding to H69ΨΨΨ.
Of particular interest is the lack of binding associated with NQVANAQ-NH2, either with
H69ΨΨΨ or H69UUU, which suggests that the presence histidine at position 6 is
essential for modified or unmodified RNA binding.

Figure 3.20 Titration plot of ESI MS
data for NQVAAHQ-NH2. Titration plot
for NQVAAHQ-NH2 bound to H69UUU.
The apparent dissociation constant is
14.3 ± 6.5 μM. No binding was observed
with H69ΨΨΨ.

Binding studies with NQVANHA-NH2, shown in Figure 3.21, revealed a 13.4 μM Kd
with H69ΨΨΨ and 47.5 μM Kd with H69UUU. This peptide has a 3.5-fold higher binding
affinity for H69ΨΨΨ RNA over H69UUU. Although this peptide shows a dominant
selectivity for H69ΨΨΨ over H69UUU, there is nearly a 3-fold lower binding affinity for
H69ΨΨΨ when compared to the parent sequence. This result suggests that further
modifications at position 7 of the peptide may not enhance binding affinity, even if the
selectivity remains favorable for the modified construct.
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Figure 3.21 Titration plots of ESI MS data for NQVANHA-NH2. A. Titration plot for
NQVANHA-NH2 bound to H69UUU. The apparent dissociation constant is 47.5 ± 9.9
μM. B. Titration plot for NQVANHA-NH2 bound to H69ΨΨΨ. The apparent dissociation
constant is 13.4 ± 4.7 μM.
To briefly summarize the binding data for the alanine scan, H69ΨΨΨ, in most cases,
had the greatest affinity over H69UUU for the modified peptides. Thus, these results
demonstrate that the parent sequence selected by phage display has the potential for
further improvement with respect to H69 binding and/or selection for modified versus
unmodified RNA. Position 6 is of particular interest since modification yielded no
observable binding, suggesting that either histidine is essential for binding in that
position or perhaps a side-chain with similar properties in that position is necessary for
binding. Modifications at position 2 revealed greater selectivity for H69ΨΨΨ over
H69UUU; however, the Kd values were not significantly different than those of the parent
sequence with the modified RNA. Changes in position 3 led to increased promiscuity in
binding with greater than 1:1 stoichiometry observed.
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3.3.3

ESI MS with arginine scan peptides - results

As shown in the previous section with the modified alanine scan, the arginine scan
also yielded results pertaining to selectivity and affinity for the two different H69 RNAs,
further supporting that the introduction of modifications can enhance binding affinity for
H69 RNAs. These results highlight the advantage of chemical synthesis over phagedisplay selection, following initial lead identification by phage display.
Binding studies with RQVANHQ-NH2, shown in Figure 3.22, revealed a 4-fold greater
affinity for H69ΨΨΨ, with a Kd of 2.4 μM, compared to H69UUU with an apparent Kd of
10.0 μM. In addition, this peptide was shown to have a 2-fold greater affinity for H69ΨΨΨ
over the parent sequence (4.6 μM).

Figure 3.22 Titration plots of ESI MS data for RQVANHQ-NH2. A. Titration plot for
RQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 10.0 ± 4.3
μM. B. Titration plot for RQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation
constant is 2.4 μM ± 0.5 μM.
Binding studies with NRVANHQ-NH2, shown in Figure 3.23, yielded very similar
dissociation constants despite the different H69 RNAs that were used for the binding
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study. The apparent Kd of 35.5 μM was determined for H69UUU and a Kd > 40 μM for
H69ΨΨΨ. A dissociation constant could not be determined because of non-specific
interactions. This result combined with the alanine scan suggests that modifying the
peptide at position 2 with a positively charged amino acid, such as arginine, does not
enhance binding affinity or selectivity.

Figure 3.23 Titration plots of ESI MS data for NRVANHQ-NH2. A. Titration plot for
NRVANHQ-NH2 and H69UUU. The apparent dissociation constant is 35.5 μM ± 4.3 μM.
B. Titration plot for NRVANHQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is
greater than 40 μM.
NQRANHQ-NH2 bound to RNA had overlapping masses with the free RNA so 5'-BiH69ΨΨΨ (biotinylated H69) and 5'-Bi-H69UUU were used to distinguish between the
complex and the free RNA. In studies pertaining to this work, biotinylated H69 was
shown to have the same binding properties as free H69 with the parent peptide. When
bound to 5'-Bi-H69ΨΨΨ, as shown in Figure 3.24, the peptide had a dissociation
constant relatively similar to the parent sequence bound to H69ΨΨΨ. Greater than 1:1
binding stoichiometry was observed with this peptide, as can be seen in Appendix A. No
binding was observed with 5'-Bi-H69UUU. Once again, in correlation with the
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modification of position 3 with the alanine scan, the arginine scan also suggests
promiscuity in binding when the valine is replaced with a different amino acid. It is
possible that a non-polar, bulky amino acid could replace valine without a change in 1:1
stoichiometry.

Figure 3.24 Titration plot of ESI MS
data for NQRANHQ-NH2. Titration
plot for NQRANHQ-NH2 bound to 5'Bi-H69ΨΨΨ.
The
apparent
dissociation constant is 6.0 ± 2.2 μM.
No binding was observed with 5'-BiH69UUU.

Binding studies with NQVRNHQ-NH2, shown in Figure 3.25, revealed a nearly 5-fold
lower affinity than the parent peptide, suggesting that an alanine at position 4 is
necessary for high-affinity binding. The Kd with H69UUU was 21.7 μM and >20 μM for
H69ΨΨΨ since non-specific interactions made it impossible to determine an apparent
dissociation constant. This result suggests that position 4 could play a role in binding to
H69, although, further work is needed to support this hypothesis.
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Figure 3.25 Titration plots of ESI MS data for NQVRNHQ-NH2.A. Titration plot for
NQVRNHQ-NH2 and H69UUU. The apparent dissociation constant is 21.7 ± 5.7 μM. B.
Titration plot for NQVRNHQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is
greater than 20 μM.
Binding studies with NQVARHQ-NH2, Figure 3.26, revealed an apparent Kd of 16.5
μM with H69UUU and no observable binding with H69ΨΨΨ. This result supports the
previous conclusion that modification with a positively charged amino acid binding to
occur to the modified H69 construct.

Figure 3.26 Titration plot of ESI MS
data for NQVARHQ-NH2 with
H69UUU RNA. Titration plot for
NQVARHQ-NH2 bound to H69UUU.
The apparent dissociation constant is
16.5 ± 5.5 μM. No binding was
observed with H69ΨΨΨ.
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Binding studies with NQVANRQ-NH2, Figure 3.27, revealed a 3-fold worse affinity for
H69UUU, 14.4 μM, compared to H69ΨΨΨ, 4.5 μM. In this case, only the (4-) charge
state was observed and used in the calculations. Binding between this peptide and
H69ΨΨΨ, and the parent sequence (4.6 μM) with the same RNA, yielded very similar
dissociation constants. Perhaps the hydrogen-bonding potentials offered by histidine and
arginine are important for overall binding to the RNA. With no binding observed with
alanine at position 6, it's intriguing to speculate the importance of this position for overall
binding affinity and selectivity.

Figure 3.27 Titration plots of ESI MS data for NQVANRQ-NH2. A. Titration plot for
NQVANRQ-NH2 and H69UUU. The apparent dissociation constant is 14.4 ± 3.1 μM. B.
Titration plot for NQVANRQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is
4.5 ± 1.7 μM.
Binding studies with NQVANHR-NH2, as shown in Figure 3.28, revealed that binding
with H69UUU and H69ΨΨΨ produced similar dissociation constants, within the error,
between the two RNAs. This result suggests that the arginine modification at position 7
does not enhance affinity or selectivity. The dissociation constant is at least 4-fold
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greater than that of the parent sequence for H69ΨΨΨ. When comparing dissociation
constants for this peptide and the parent sequence with H69UUU, one will find that they
are very similar to one another. Due to limited availability of H69ΨΨΨ at the time of this
experiment, 5'-Bi-H69ΨΨΨ was used to attain this information.

Figure 3.28 Titration plots of ESI MS data for NQVANHR-NH2. A. Titration plot for
NQVANHR-NH2 bound to H69UUU. The apparent dissociation constant is 20.5 ± 2.8
μM. B. Titration plot for NQVANHR-NH2 bound to 5'-Bi-H69ΨΨΨ. The apparent
dissociation constant is 31.8 ± 7.3 μM.
3.4

Summary of alanine and arginine scanning

Mass spectrometry studies with H69 RNAs and the alanine and arginine scan peptides
gave informative results regarding which amino-acid positions are important for affinity
and selective binding. Results from this study also validated the original selection
process197 with emphasis of binding taking place through the H69 loop region, although
interactions with the H69 stem cannot be ruled out. This validation is clear when
comparing apparent dissociation constants between the modified and unmodified H69
RNA constructs, which is further discussed in Section 3.4.1 and 3.4.2. The results also
support the fact that peptide ligands can be designed to target RNA containing modified
nucleotides.
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Table 3.2 compiles the information from each binding study in addition to providing a
binding ratio of the averaged Kds from H69ΨΨΨ and H69UUU. The lower the ratio, the
greater affinity the peptide has for H69ΨΨΨ over H69UUU. H69 RNA binding ratios
could not be obtained in instances in which binding was not observed or could not be
obtained due to non-specific interactions.
Table 3.2 Apparent Kds of alanine and arginine scan peptides with H69 RNAs
Peptide
AQVANHQ-NH2
NAVANHQ-NH2
*NQAANHQ-NH2
NQVANHQ-NH2
NQVAAHQ-NH2
NQVANAQ-NH2
NQVANHA-NH2
RQVANHQ-NH2
NRVANHQ-NH2
*NQRANHQ-NH2
NQVRNHQ-NH2
NQVARHQ-NH2
NQVANRQ-NH2
NQVANHR-NH2

Kd H69ΨΨΨ, μM
NBO
4.6 ± 1.8
5.0 ± 1.0
4.6 ± 1.7
NBO
NBO
13.4 ± 4.7
2.4 ± 0.5
>40
†6.0 ± 2.2
>20
NBO
4.5 ± 1.8
†31.8 ± 7.3

Kd H69UUU, μM
9.9 ± 2.1
52.8 ± 9.7
1.0 ± 0.5
22.9 ± 5.6
14.3 ± 6.5
NBO
47.5 ± 9.9
10.0 ± 4.3
35.5 ± 10.1
NBO
21.7 ± 5.7
‡16.5 ± 5.5
14.4 ± 3.1
20.5 ± 2.8

H69UUU/H69ΨΨΨ
12
0.2
5
3.5
4.2
3.2
0.6

NBO-no binding observed; *2:1 Peptide to RNA stoichiometry observed; †5'-Bi-H69ΨΨΨ
RNA used instead of H69ΨΨΨ; ‡ Only the (4-) charge state was observed.
In addition to Table 3.2, Figure 3.29 provides a visual representation of binding ability
of each peptide. The Kd values for each peptide tested were normalized to that of
NQVANHQ-NH2 with H69ΨΨΨ. The comparison reveals that amino acid substitutions
can lead to peptides with varying affinity to H69 relative to the parent peptide identified
from phage display. One peptide (RQVANHQ-NH2) showed almost 2-fold greater affinity
for H69ΨΨΨ than the parent, whereas seven peptides had more than a 50% reduction in
affinity

(AQVANHQ-NH2,

NQVAAHQ-NH2,

NQVANHA-NH2,

NRVANHQ-NH2,

NQVRNHQ-NH2, NQVARHQ-NH2, and NQVANHR). Perhaps surprisingly, half of these
peptides with significantly reduced affinity contained arginine, showing that additional
positive charge does not necessarily enhance RNA binding. With the exception of one
peptide (NQAANHQ-NH2), all of the peptides tested had significantly lower affinity for
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H69UUU compared to H69ΨΨΨ, and five showed enhanced specificity for H69ΨΨΨ over
H69UUU (NAVANHQ-NH2, NQVANHQ-NH2, NQVANHA-NH2, RQVANHQ-NH2, and
NQVANRQ-NH2). Note that the plot in Figure 3.29 does not take into account greater
than 1:1 binding stoichiometries as observed with modifications in position 3. Based on
this result, RQVANHQ-NH2 provides the best relative binding affinity of the peptides
tested to H69ΨΨΨ, and good (4-fold) selectivity for H69ΨΨΨ over H69UUU.

Figure 3.29 Bar graph representation of modified peptides and H69 RNAs relative
to NQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation constant of
NQVANHQ-NH2 bound to H69ΨΨΨ divided by the apparent dissociation constant of
each peptide with respective H69 RNA yields a numerical value. Any value above one
represents a peptide that bound to its target with greater affinity than the parent peptide
to H69ΨΨΨ. Spaces where no bar is observed represents peptides that produced no
binding complex with H69 RNA.
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3.4.1 Peptide binding with H69ΨΨΨ
For H69ΨΨΨ, RQVANHQ-NH2 has a 2-fold better affinity than the parent sequence. A
positively charged amino acid with H-bonding potential at position 1 enhanced binding,
whereas replacing the asparagine with alanine, a non-polar, non-bulky amino acid
abolished binding. This result suggests a specific interaction between asparagine and
H69ΨΨΨ.
Replacing position 2 of the parent peptide with alanine did not alter the dissociation
constant relative to the parent, suggesting that the glutamine in that position may not be
imperative for RNA binding. Alternatively, there could be a specific interaction with the
–CH3 functionality of alanine. When position 2 was replaced with an arginine, the
binding affinity decreased significantly (>10-fold), suggesting that the positive charge or
long chain on the amino acid impairs the peptide interaction. This result suggests a
preference for hydrophobic functional groups at position 2 over charged residues.
Peptides

with

modifications

at

position

3,

regardless

of

the

composition

(alanine/arginine), have comparable affinity to that of the parent sequence, suggesting a
minimal role in H69ΨΨΨ binding. However, greater than 1:1 stoichiometry was observed
upon RNA binding, which suggests that position 3 in the parent may be important for
inhibiting peptide-peptide interactions. Since these studies were limited to alanine and
arginine, it would be of interest to see if other amino acids that are nonpolar and with
similar levels of bulkiness, such as leucine or isoleucine, can also maintain the 1:1
stoichiometry and affinity. Interestingly, this position also played a role in specificity for
modified over unmodified H69 RNA, which will be discussed in the next section.
Position 4 is an alanine in the parent sequence, so no change was made in the alanine
scan. A 4-fold lower binding affinity was observed when the residue was modified with
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arginine, suggesting that alanine (or an amino acid with similar properties) is important
for binding to H69ΨΨΨ.
Position 5 variant peptides yielded no observable binding to H69ΨΨΨ, signifying that
asparagine, or perhaps an amidated amino acid, is essential for binding to H69.
Replacing the histidine at position 6 with alanine also abolished binding, whereas the
arginine variant behaved similarly to the parent. Since both side-chains of histidine and
arginine have hydrogen-binding capabilities, perhaps this attribute is important for
H69ΨΨΨ binding. Position 7 modifications both led to worse binding to modified H69
RNA, suggesting the importance of glutamine or other amidated amino acids for binding.
Although the parent sequence NQVANHQ did not reveal homology with amino acid
sequences associated with ribosomal recycling factors and proteins with contact sites to
H69, there are amino acids within the sequence present with individual amino acids of
the ribosomal recycling factor (V20, H23, N24),172 suggesting that functional groups
present in the peptides studied are essential for selective binding.
3.4.2 Peptide binding with H69UUU
This summary will compare the apparent dissociation constants between peptide
variants bound to the unmodified version of H69 (H69UUU). Modifying position 1 with
alanine or arginine led to a 2-fold better affinity to H69UUU in both cases. This result
differs from that with H69ΨΨΨ, suggesting a specific interaction with the RNA loop.
Position 2 alterations led to 2-fold worse binding profiles in both cases. This result is
not necessarily similar to that of H69ΨΨΨ binding, in which a modification with alanine
led to an equivalent apparent dissociation constant to the parent bound to H69ΨΨΨ. The
arginine-modified peptide bound similarly to H69ΨΨΨ with overlapping error between the
two RNAs. In the case of RNA binding, neither peptide modification bound better than
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the parent with H69ΨΨΨ, suggesting that position 2 with a glutamine, or similar amino
acid is important for binding interactions to take place with H69UUU. Position 3 variants,
when bound with alanine, also yielded results with greater than 1:1 binding stoichiometry
as observed with H69ΨΨΨ (titration spectra can be observed in Appendix A), despite the
fact that a higher affinity was identified, further supporting that the valine, or an amino
acid with similar properties, is needed for binding interactions to occur.
Position 4 when modified with arginine did not lead to a significant change in binding
profiles against H69UUU when compared to the same peptide binding to H69ΨΨΨ,
suggesting that position 4 could be further modified to find potentially better ligands for
the unmodified RNA. This is further supported when binding is 4-fold worse than the
parent sequence binding to H69ΨΨΨ. Position 5 variants didn't lead to higher affinity
ligands (~4-fold worse affinity) compared to the parent sequence suggesting that the
asparagine and alanine residues are not important for binding to H69UUU. This result is
interesting because a positively charged amino acid had about the same effect on
binding as a non-bulky, non-polar amino acid.
Position 6 (alanine-modified peptide) had no binding to H69ΨΨΨ. Position 7, when
modified with alanine, led to a peptide with 2-fold lower binding affinity compared to the
parent bound to H69UUU. Modifying this position with arginine produced a peptide that
bound with similar binding affinity to that of the parent sequence bound to H69UUU.
Results pertaining to binding with H69UUU provided evidence of selective binding to
modified nucleotides; that is, being able to compare directly with H69ΨΨΨ studies
revealed differences in apparent Kds indicative of selective binding. It would also be
interesting to have modified peptides selective for the unmodified H69 in order to disrupt
ribosomal association. Since the modifications on H69 are added post-transcriptionally,12
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it is hypothesized that these modifications occur prior to subunit association when H69
exposed for enzymatic activity.
3.5

Histidine modifications to NQVANHQ-NH2 with H69 RNA binding

Due to the fact that replacement of histidine with alanine at position 6 led to a complete
loss of binding to H69, the possible role of histidine in RNA binding was of interest. Four
additional peptides were synthesized, shown in Figure 3.30, to determine if the
presence of histidine at positions 5 or 7 of the peptide sequence would enhance RNA
binding. Two peptides contained an alanine at position 6 in place of histidine, with a
histidine residue located at position 5 or 7. This would help determine whether histidine
is needed at position 6 specifically, or if the presence of histidine was sufficient for
selective and/or strong binding. The other two peptides contained a histidine in position
6, as with the parent sequence, with an additional histidine at position 5 or 7. These two
peptides would help determine if the additional histidine had the ability to enhance
binding affinity for H69.

Figure 3.30 Four histidine-modified peptides were synthesized for binding
interaction studies. Left, the parent sequence NQVANHQ-NH2 underwent histidine
modification in positions 5 and 7 to produce NQVAHHQ-NH2 and NQVANHH-NH2,
respectively. Right, the alanine modified peptide at position 6 underwent further
modification with histidine at positions 5 and 7 to produce NQVAHAQ-NH2 and
NQVANAH-NH2, respectively.
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A one-shot binding study, shown in Figure 3.31, was performed with each of the four
peptides using 3 μM H69ΨΨΨ and 20 μM of each of the four histidine scan peptides.
These conditions had been established previously with the parent peptide; therefore, a
direct comparison could be made regarding relative affinity of the newly synthesized
peptides and the parent sequence.

Figure 3.31 One-shot binding studies of histidine-modified peptides with H69ΨΨΨ
rRNAs. Four peptides containing histidine modifications (underlined) relative to the
parent sequence NQVANHQ-NH2 were tested to determine if binding exists with
H69ΨΨΨ rRNAs.
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The peptide NQVAHAQ-NH2 yielded no observable binding to H69ΨΨΨ, so the oneshot experiment was repeated with 30 μM peptide, producing the same result. This
finding correlates well with the alanine and arginine scan results, Table 3.2, in which no
binding to H69ΨΨΨ was observed when modifications were made at position 5.
Similarly, alanine replacement at histidine of position 6 had abolished binding to
H69ΨΨΨ. Therefore, binding was not recovered by addition of histidine at the
neighboring position. Figure 3.31 provided a one-shot profile of the four synthesized
peptides compared to the parent sequence. The intensity values of the peptide-RNA
complex were compared, and one peptide (NQVAHHQ-NH2) was a promising compound
with potentially better binding than the parent sequence. However, a titration with
peptide NQVAHHQ-NH2 (Cf = 0-60 μM) and H69ΨΨΨ (Cf = 3 μM) was completed
yielding a dissociation constant of 16.0 ± 3.5 μM (Figure 3.32). This result indicates an
approximately 3-fold lower binding affinity relative to the parent, providing further support
that position 5 (N) is important for H69ΨΨΨ binding.

Figure 3.32 Binding curve for
NQVAHHQ-NH2 with H69ΨΨΨ. The
curve for NQVAHHQ-NH2 with H69ΨΨΨ
has an apparent dissociation constant of
16.0 ± 3.5 μM.
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3.6

Conclusions

This study provides information regarding the development of peptide ligands to
selectively target H69 RNAs. Although the original selection was for the wild-type H69,
studying both the modified and unmodified constructs gave further proof that ligands can
be designed to target modified nucleotides as many of the modified peptides studied
revealed selectivity for H69ΨΨΨ over H69UUU. This also validates the argument that
tight binders are unlikely to be identified using the phage display technique due to the
RNA target being an essential part of the amplification process; however, it also
supported the screening rationale in the original phage experiments leading to the
identification of a peptide ligand that selectively targeted the modified nucleotides
present in the loop region of H69 RNA. The alanine and arginine scans provided new
information about the roles of each amino acid in the selected sequence and which ones
play key roles in H69 binding and/or selectivity. Although the peptides used in this
particular study are unlikely candidates for antibiotic development, further modifications
could make that goal a reality in addition to helping elucidate the function of H69.
Modifying position 3 with alanine provided evidence of strong binding, although
selectivity was greatly decreased. Modification of position 1 with arginine provided the
most selective peptide to H69ΨΨΨ with a 2-fold greater affinity than the parent
sequence. Future studies may give us a clearer understanding of how these peptides
may bind to their target as well as the impact on ribosome function, since our results
reveal that certain positions with specific amino acid allocations are more important than
others.
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CHAPTER 4 BIOPHYSICAL AND BIOCHEMICAL BINDING STUDIES OF SELECTED
H69 PEPTIDES
4.1 Introduction
From the ESI MS binding studies with modified H69 peptides and H69UUU and
H69ΨΨΨ rRNAs, a few were selected for further characterization in order to obtain more
detailed information regarding these binding interactions. Techniques used to obtain
information were circular dichroism (CD) and isothermal titration calorimetry (ITC). Note
that CD experiments were performed in collaboration with Dr. Jun Jiang, a post-doc
working with the Chow group, and results revealed no significant change between free
RNA and RNA-peptide complex. Peptide samples were provided by using SPPS and
HPLC purification as described in Section 2.2, and RNA samples were either obtained
through transcription (by Dr. Jun Jiang) or purchased as synthetic constructs from
Dharmacon. In addition to these techniques, a visual screening assay was developed in
order to identify novel peptide ligands in future RNA-targeting studies.
4.2 Biophysical experiments of H69 RNA and selected H69 peptides
4.2.1 Circular dichroism of selected modified peptides with H69 RNAs
Circular dichroism, described in Section 2.6 of this work, was used to identify changes
regarding free RNA and peptide species relative to complex formation. Since
RQVANHQ-NH2 had been shown to bind with higher affinity through ESI MS than the
parent sequence (NQVANHQ-NH2) identified previously,197 it was of interest to study this
binding interaction further. Figure 4.1 provides a set of data corresponding to H69UUU
RNA (unbound, Cf = 4 μM), the peptide NQVANHQ-NH2 (unbound, Cf = 112 μM), and
complex between H69UUU RNA and NQVANHQ-NH2 (Cf = 4 μM RNA: 126 μM peptide).
In addition, the change (Δ) in peptide and RNA was also visualized in order to determine
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whether changes due to the binding event occurred. Equations 4.1 and 4.2 define how
the difference in spectra (Δ) for peptide or RNA, respectively, was obtained from the CD
data.
Equation 4.1: Δpeptide = CD of RNA-peptide complex - CD of RNA
Equation 4.2: ΔRNA = CD of RNA-peptide complex - CD of peptide
The unbound peptide showed a characteristic profile for random coil secondary
structure, as shown in Figure 2.3, which correlates exactly with an independent CD
experiment with NQVANHQ-NH2 performed previously (data not shown). The random
coil secondary structure provides evidence that these peptides are flexible and may not
depend on a specific conformation for RNA binding.
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Figure 4.1 Circular dichroism spectra of NQVANHQ-NH2 with unmodified H69. A
spectral range from 190 to 320 nm was used to observe circular dichroism changes for
NQVANHQ-NH2, H69UUU, and NQVANHQ-H69UUU complex. H69UUU (yellow)
overlaps with the H69UUU + NQVANHQ (green) spectrum. The data shown in this figure
were obtained by Dr. Jun Jiang.
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When observing changes in RNA conformation, one normally looks in the 260 nm
region as absorbance is observed at this region due to the structural components of
RNA. As shown in Figure 4.1, there was no discernable difference between unbound
and bound H69UUU to peptide, suggesting that the binding event may not change the
global conformation of the RNA or that perhaps a binding event had not occurred. What
was most interesting in this figure lies within the 190 to 230 nm range as shown in
Figure 4.2. In this range, the most definitive changes between bound and unbound
species of RNA and peptide were observed.
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Figure 4.2 An expanded view of CD spectra of NQVANHQ-NH2 and H69UUU. An
expanded view of the CD profile previously shown in Figure 4.1 ranged from 190 nm to
230 nm. A change due to binding of H69UUU RNA and NQVANHQ-NH2 was observed
at approximately 193 nm.
At approximately 193 nm, NQVANHQ-NH2 (outlined in red) most closely represents a
random coil secondary structure; however, when bound with H69UUU RNA (outlined in
green) a definitive change was observed suggesting α-helical properties. The α-helix
secondary structure of peptides and proteins is characterized by three CD peaks, one
positive (π-π*) from 190-195 nm, and two negative shown at 208 nm (π-π*) and 222 nm
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(n-π*), respectively.213 Although the data shown in Figure 4.2 doesn't exactly show all
three identifiers, two are observed suggesting that the peptide takes on a more defined
conformation when bound to the RNA. To further support this, note that free RNA
(outlined in orange) had a different pattern from that of the RNA-peptide complex in this
same region, further suggesting that a conformational change with the peptide may be
occurring. Based on these data, the suggestion is that the peptide may be the only
moiety within the sample making an observable change, which could explain why no
difference was observed at 260 nm for the RNA (Figure 4.1).
When this experiment was repeated with RQVANHQ-NH2 (Cf = 112 μM), a modified
peptide identified to have a greater affinity than the parent sequence, similar findings
were observed as shown in Figure 4.3.
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Figure 4.3 Circular dichroism spectra of RQVANHQ-NH2 with unmodified H69 RNA.
A spectral range from 190 to 320 nm was used to observe circular dichroism changes for
RQVANHQ-NH2, H69UUU, and RQVANHQ-H69UUU complex. H69UUU RNA (orange)
overlaps with the H69UUU + RQVANHQ spectrum after 220 nm. The data shown in this
figure were obtained by Dr. Jun Jiang.
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Figure 4.3 yielded a similar profile shown in Figure 4.1 in which H69UUU RNA
revealed no difference to the complex at 260 nm; however, a change was observed in
the 190-230 nm region as shown in Figure 4.4. Although the difference associated with
complex formation was not as dramatic as that observed with NQVANHQ-H69UUU, the
change in peptide spectrum was most discernable at 193 nm, suggesting that
conformational changes of the peptide did occur upon RNA binding.
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Figure 4.4 An expanded view of CD spectra of RQVANHQ-NH2 and H69UUU. An
expanded view of the CD profile previously shown in Figure 4.3 ranged from 190 nm to
230 nm. A change due to binding of H69UUU RNA and RQVANHQ-NH2 was observed
at approximately 193 nm.
The CD experiment was repeated with modified H69 RNA (Cf: 14.5 μM H69ΨΨΨ, 116
μM peptide) and H69 peptides. The first complex studied was between H69ΨΨΨ and
NQVANHQ-NH2 as shown in Figure 4.5. The results yielded slightly different results
when compared to the unmodified construct in regards to peptide binding. The spectra
share similarities at 260 nm, which revealed no observable change; that is, no peak shift
or hypo/hyperchromicity was observed when H69ΨΨΨ was bound to NQVANHQ-NH2.
When focused on that result alone, it would appear that the peptide binding does not
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change the overall RNA conformation as one might have expected when a binding event
has occurred. The greatest change was observed in the 190 to 230 nm wavelength
region where it appeared that the peptide conformation had changed upon binding to
H69ΨΨΨ, but not in the same fashion as it had with the unmodified construct.
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Figure 4.5 Circular dichroism spectra of NQVANHQ-NH2 with modified H69. A
spectral range from 190 to 320 nm was used to observe circular dichroism changes for
NQVANHQ-NH2, H69ΨΨΨ, and NQVANHQ-H69ΨΨΨ complex. H69ΨΨΨ RNA (orange)
overlaps with H69ΨΨΨ and NQVANHQ after 220 nm. The data shown in this figure were
obtained by Dr. Jun Jiang.
Since it is unclear from the original figure which specific changes occurred, Figure 4.6
shows an expanded view with a wavelength range of 190 to 230 nm.
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Figure 4.6 An expanded view of CD spectra of NQVANHQ-NH2 and H69ΨΨΨ. An
expanded view of the CD profile previously shown in Figure 4.5 ranged from 190 nm to
230 nm.
In this case, the binding complex shows a similar profile to the free peptide; that is, a
random coil profile. Although a change was observed when bound, it appears that the
peptide remains more flexible rather than displaying a specific structural conformation
upon RNA binding. This is a particularly interesting finding since it contrasted with
findings with the unmodified RNA construct.
Similar findings were observed when the CD experiment was performed with
RQVANHQ-NH2 and H69ΨΨΨ as shown in Figure 4.7. At 260 nm, no observable
change between complex and free RNA was observed, suggesting that the overall
conformation of the RNA construct remained the same.
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Figure 4.7 Circular dichroism spectra of RQVANHQ-NH2 with modified H69. A
spectral range from 190 to 320 nm was used to observe circular dichroism changes for
RQVANHQ-NH2, H69ΨΨΨ, and RQVANHQ-H69ΨΨΨ complex. The H69ΨΨΨ RNA
spectrum overlaps with H69ΨΨΨ + RQVANHQ after 220 nm. The data shown in this
figure were obtained by Dr. Jun Jiang.
An expanded view as shown in Figure 4.8 revealed results similarly observed with
NQVANHQ-NH2 bound to H69ΨΨΨ, in which a shift was observed upon binding;
however, the peptide conformation was still a random coil. Although a change in peptide
and RNA was observed in the wavelength region of 190 to 220 nm, the spectral trends
remained very similar, suggesting that a pronounced physical change may not have
occurred upon binding.
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Figure 4.8 An expanded view of CD spectra of RQVANHQ-NH2 and H69ΨΨΨ. An
expanded view of the CD profile previously shown in Figure 4.7 ranged from 190 nm to
230 nm.
4.2.2 Isothermal titration calorimetry (ITC) with RQVANHQ-NH2 and H69UUU
As discussed in Sections 2.6.2 through 2.6.4, ITC experiments were performed with
RQVANHQ-NH2 and H69UUU. The H69UUU was transcribed, purified, and desalted by
Dr. Jun Jiang. The RQVANHQ-NH2 was synthesized and purified as described in
Section 2.2. Parameters such as temperature, buffer composition, and titrate (RNA) and
titrant (peptide) concentrations were tested in order to determine the most ideal
conditions for the experiments. The area under the curve of μcal/sec versus minutes was
integrated for each injection (Origin V.7.0, Microcal, Inc.) to determine the heat
pertaining to each injection. These parameters were inspired by literature covering RNA
and protein/peptide binding studies.214, 216, 232
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Figure 4.9 ITC with RQVANHQ-NH2 and H69UUU in phosphate buffer A. Titrant
(RQVANHQ-NH2) was systematically injected into the sample cell containing only
phosphate buffer A at 25 °C (no titrate (RNA), black) in order to determine the
thermodynamic profile used to subtract. The thermodynamic profile representing
RQVANHQ-NH2 as the titrant and H69UUU as the titrate is outlined in red.
For each buffer used as well as any change in concentration regarding the titrant
(peptide, 500 μM stock) and titrate (RNA, 3 μM stock), a run without the titrate to
determine the background for later subtraction during the data analysis was performed.
Figure 4.9 shows data for a run without titrate and data with the titrate. Phosphate buffer
A (10 mM potassium phosphate, 100 mM KCl, pH 7.2) The overall thermodynamic
profile was found to be exothermic based on the subtraction of the peptide titrated into
buffer from peptide titration into RNA (Figure 4.10). As shown in Figure 4.9, the heat of
dilution is very high for the background and is indicative of high salt being present. This
was not surprising since the peptide contained salt despite efforts to remove it during
purification.
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Figure 4.10 ITC of RQVANHQ-NH2 and H69UUU in phosphate buffer A. The result
from peptide titration into phosphate buffer A was subtracted from the result obtained
with the peptide titration into RNA. The overall thermodynamic profile is exothermic.
Since it was not possible to remove the endogenous salt in the peptide sample, nor
was it possible to determine how much salt was actually present outside of the buffer
conditions, an argument was made that if the buffer salt concentration was high enough,
the salt present in the peptide sample would become negligible when compared to the
overall solution. To address this possibility, the salt concentration was increased in the
phosphate buffer (phosphate buffer B) to 150 mM potassium chloride with the reasoning
that the higher the salt concentration of the overall solution, the salt present in the
peptide sample would then be negligible and no longer interfere with the thermodynamic
profile associated with peptide binding to RNA. Figure 4.11 shows data correlating to a
run in phosphate buffer B (10 mM potassium phosphate, 150 mM potassium chloride,
pH 7.2). The RNA and peptide stock concentrations remained the same (3 μM and 500
μM, respectively).
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Figure 4.11 ITC with RQVANHQ-NH2 and H69UUU in phosphate buffer B. Titrant
(RQVANHQ-NH2) was systematically injected into the sample cell containing only
phosphate buffer B at 25 °C (no titrate (RNA), black) in order to determine the
thermodynamic profile used to subtract. The thermodynamic profile representing
RQVANHQ-NH2 as the titrant and H69UUU as the titrate is outlined in red.
Figure 4.11 revealed a much higher thermodynamic profile than what was seen with
phosphate buffer A, yet the same trend was observed. It appears that salt concentration
does impact the overall thermodynamic profile and increasing the salt concentration in
the buffer did not yield the negligible effects that were anticipated; however, it is
important to note that the difference obtained from subtracting the thermodynamic profile
of the peptide into buffer from thermodynamic profile of the peptide into RNA still showed
an exothermic reaction as shown in Figure 4.12.
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Figure 4.12 ITC of RQVANHQ-NH2 and H69UUU in phosphate buffer B. The result
from peptide titration into phosphate buffer B was subtracted from the result associated
with peptide titration into RNA. The overall thermodynamic profile is exothermic.
The end result of these experiments despite testing different buffer conditions and
temperatures (data was also collected at 37 °C, not shown) revealed that salt presence
in the samples may interfere with the overall goal of observing binding interactions
between H69UUU and the modified peptide ligand RQVANHQ-NH2. It is likely that
similar results would be observed with H69ΨΨΨ binding studies as the salt problem
resides with the peptide sample. These peptides are extremely hydrophilic and often
come out in pure water or exceedingly low acetonitrile gradients (0-5%) during HPLC
purification. Salt is traditionally removed in the 0-5% acetonitrile gradient. Of particular
importance is the exothermic profiles identified despite the buffer choice, suggesting that
binding events are taking place. Another concern was the possibility of peptide
aggregation since it was observed at high concentrations of peptide in ESI MS
experiments. In the case of ITC, aggregation may not have played a role since the
thermodynamic profiles associated with peptide in buffer did not yield information
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pertaining to a binding event independent of RNA. A possible future experiment would
be to reverse the roles of the titrate and titrant so that RNA is then titrated into peptide.
Perhaps if the salt endogenous to the peptide is already present in the sample cell, its
presence may not interfere with the titration of the RNA into the peptide.
4.3 The design and optimization of a visual screening assay to select peptide
ligands that target H69 RNAs
4.3.1 Introduction to the RNA-peptide fluorescence screening assay
Screening peptides with ESI MS has yielded helpful information regarding the
selectivity and affinity of modified heptamers to target RNA; however, the process of
attaining this information was very time consuming in terms of both the synthesis and
purification of individual peptides needed to perform the experiments. In many cases, the
peptides screened for dissociation constant determination consumed large amounts of
peptide and RNA only to find that they were not better binders to the target RNA. It also
required a lot of RNA and peptide that could not be recovered and re-used. This
challenge established a need for an assay that can screen libraries of peptide versus
individual peptides. High-affinity peptides identified from a library-screening assay can
then be synthesized, purified, and tested for selectivity and affinity. To address this
challenge, a visual assay using quantum dots (Qdot) as fluorophores, flow cytometry as
the method to screen hits, and mass spectrometry to identify the screened hits was
developed. Peptides identified by this approach can then undergo binding studies with
RNA to determine the relative affinity and selectivity. To test the assay design, details of
which can be found in Section 2.8, a small set of peptide variants (position 1) were
synthesized using manual SPPS as summarized in Table 4.1.
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Table 4.1 Peptides synthesized for the visual assay
Sample #
Peptide
Chemical
Monoisotopic
for FC*
Formula
Mass (g/mol)
sorting
8
NQVANHQ-NH2
C32H52N14O11
808.39
6
AAAAAAA-NH2
C21H38N8O7
514.29
RQVANHQ-NH2
9
C34H58N16O10
850.45
DQVANHQ-NH2
C32H51N13O12
809.38
MQVANHQ-NH2 C33H55N13O10S1
825.39
FQVANHQ-NH2
C37H55N13O10
841.42
GQVANHQ-NH2
10
C30H49N13O10
751.37
PQVANHQ-NH2
C30H53N13O10
755.40
SQVANHQ-NH2
C31H51N13O11
781.38
RQVANHQ-NH2
C34H58N16O10
850.45
*FC = flow cytometry
4.3.2

Role in visual
assay
positive control
negative control
ESI MS selected
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant
position 1 variant

Sample submission for flow cytometry experiment

Samples were prepared as described in Section 2.8.4. Additional fresh 1x PBS was
provided with the samples. The following lists samples that were submitted for flow
analysis and sorting: 1) blank beads; 2) blank beads + Qdot 605; 3) blank beads + RNA
+ Qdot 605; 4) RNA + Qdot 605; 5) Positive control + RNA + Qdot 605; 6) Negative
control + RNA + Qdot 605; 7) Mix of positive and negative control + RNA + Qdot 605
(with sorting); 8) NQVANHQ + RNA + Qdot 605 (with sorting); 9) RQVANHQ + RNA +
Qdot 605 (with sorting); and 10) Position 1 variants + RNA + Qdot 605 (with sorting).
Blank beads were 10 μm Tentagel without peptide. The first three samples were
designed to observe whether non-specific binding of either the streptavidin-coated Qdot
605 (Qdot 605) and/or the Qdot 605 bound to the biotinylated H69ΨΨΨ (5'-Bi-H69ΨΨΨ)
RNA occurred with the blank bead. Sample four was submitted to determine whether
RNA complexed to Qdot 605 would be observed as a false-positive during the flow
cytometry experiment. Samples five through ten contained beads with synthetic peptide
with a photocleavable linker on each. Sample five contained beads with NQVANHQ and
was considered the positive control due to its previous identification using fluorescence
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as described previously.227 In addition, preliminary studies with this instrumentation had
shown positive results with this peptide each time. Sample six contained Tentagel beads
with AAAAAAA, which is a peptide that did not bind to H69 RNA in preliminary
experiments. Samples seven through ten were sorted into individual wells of a 96-well
plate. Sample seven contained a mixture of the positive and negative control. Sample
eight contained the parent sequence (essentially the positive control submitted for
sorting). Sample nine contained RQVANHQ, a modified H69 peptide identified to bind
with greater affinity than the parent sequence using ESI MS. Sample ten contained
seven members of the position 1 variant pool, with peptide identities and corresponding
chemical formulas and masses given in Table 4.1. Samples were prepared as described
in Section 2.8.4. and submitted to the Microscopy, Imaging and Cytometry Resources
Core at Wayne State University, School of Medicine. This service was performed by Eric
Van Buren, flow cytometry core manager, using a SH800 cell sorter (model LESH800ZFP, Sony Biotechnology, Tokyo, Japan).
4.3.3

Data analysis from the flow cytometry core of submitted samples

The flow cytometry core provides data pertaining to each sample submitted in three
separate figures. The first, illustrated in Figure 4.13, represents the template for a dot
plot analysis in which each bead is cycled through the instrument and two lasers
systematically pass light through each bead. The forward scatter (FCC) provides
information related to the size of the bead/particle/cell that it hits and is represented in
the x-axis. The side scatter (SSC) provides information related to the complexity of
bead/particle/cell; that is, what's on the surface (smooth, rigid, etc.). Combined, it sorts
the beads to populations correlating to sample population(s) to be further analyzed and
removing samples pertaining to debris. The pound sign shown in the top right corner in
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this figure represents the percentage of beads/particles/cells from the total introduced in
the instrument selected for further analysis. The unit corresponding with the x-axis and
y-axis correlates to the number of beads/particles/cells present in the whole sample
introduction to the instrument.

Figure 4.13 Dot plot determination of the sample population used in flow
cytometry. Samples introduced into the flow cytometry instrumentation are exposed to
forward and side scattering light providing information on size and complexity of each
sample. The dot plot systematically determines the differences between a sample
population and debris present in the buffer.
From the initial dot plot, the selected sample population is further analyzed to separate
single beads (singlets) from aggregates (doublets, etc.) as shown in Figure 4.14. As the
bead/particle/cell passes through the flow cytometer, light reveals aggregates to have
the same height as singlets (y-axis); however, the x-axis represents the peak area of
each sample passing through and this difference creates new populations separating
aggregates from single beads. The pound sign shown within the singlet gating
population represents the percentage of this overall selection found to be singlets. This
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population undergoes the final analysis providing fluorescence information on the
sample. Note that most publications do not usually provide dot plots, such as Figures
4.13 and 4.14, as this is the physical selection and processing that leads to the data
desired from sample submission. The dot plots will be shown for each of the peptide and
control to draw attention to sample counts and debris present in each whole sample
submitted, since this is a new application of flow cytometry.

Figure 4.14 Dot plot determination separating singlets and aggregates from the
selected population. The population selected from the initial sample submission
undergoes further analysis to select for single beads over aggregates.
The third and final dot plot diagram shown is the most important for experimental
analysis. Figure 4.15 shows a dot plot providing a population determination of positive
versus negative fluorescent hits. Since it is known that Tentagel beads with peptide
synthesized on their surface autofluoresce green,227 it is important to be able to identify
true positive hits over negative ones. The x-axis represents green emission at 525 nm ±
25 nm (525/50) and the y-axis represents red emission at 600 ± 60 nm (600/60).
Quantum dot 605 (Qdot 605) emits at 605 nm. The gate represented in Figure 4.15 was
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determined specifically for the experiment displayed in this report. Since a negative
control was submitted, that population was taken into account with the autofluorescence
so that anything not in that population would be seen as a positive hit. The negative
region also accounts for background signal. The pound sign within the gated positive-hit
region represents the percentage of beads that had Qdot 605 emission.

Figure 4.15 Dot plot determination of Qdot 605 emission. Green emission (525 ± 25
nm) versus red emission (600 ± 30 nm) was established to separate true positive hits
from false-positives known to fluoresce green.
Before discussing the individual results, it is important to understand that these results
are not quantitative. The suggested improvements for further work will be discussed in
the future directions chapter (Chapter 6). Certain parameters may affect a given
population so that it isn't quantitative, such as degree of binding, possible degradation,
amount of RNA, and Qdot molecules available for binding relative to the number of
beads available, etc. This will be discussed further after the results are shown.
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Sample one contained 10 μm Tentagel beads without synthetic peptide and the results
are shown in Figure 4.16. When compared to dot plots of other samples, one can clearly
see the overall uniformity of the beads giving concentrated populations (red). This is
likely due to the fact that the samples do not have synthetic peptide and therefore have
lower complexity compared to its synthetic counterpart.

Figure 4.16 Sample one – blank beads diagrams for bead selection. Entire sample
of blank beads (Event count 25000) introduced into the instrument are visualized in the
left panel and a topographical observation correlating to bead colonies with similar size
and shape were analyzed to omit debris present in the sample. The middle panel shows
the population selected for Qdot 605 emission omitting aggregates. The right panel
represented Qdot 605 emission detection (top left segregated corner) versus green
autofluorescence and background emission. The value in the top left corner of the right
panel represents the percentage of beads in that dot plot shown to have positive 605 nm
emission.
Figure 4.17 shows data of blank beads incubated with Qdot 605 to determine whether
the streptavidin-coated quantum dot could non-specifically bind to the beads without
peptides. As with the blank bead control, the right panel shows that very few beads
(19/21269) have any emission profile. This results supports that non-specific binding of
the bead to Qdot 605 did not occur.

120

Figure 4.17 Sample two – blank beads with Qdot 605 diagrams for bead selection.
The entire sample of blank beads (Event count 23763) with Qdot 605 incubation were
introduced into the instrument and visualized in the left panel to separate the sample
population from debris. The middle panel represented the population selected for further
analysis as it selected for singlet beads over aggregates and the right panel represented
the emission profile congruent with Qdot 605 binding.
Figure 4.18 shows data of blank beads incubated with 5'-Bi-H69ΨΨΨ RNA followed by
incubation with Qdot 605. This control sample was designed to determine whether the
RNA could bind to blank beads, which would in turn be visualized since the biotinylated
RNA couples to the Qdot 605. This result also indicated that non-specific binding with
the RNA-Qdot complex did not occur.

Figure 4.18 Sample three – blank beads with biotinylated RNA and Qdot 605
diagrams for bead selection. The entire sample of blank beads (Event count 25000)
with RNA and Qdot 605 incubation were introduced into the instrument and visualized in
the left panel to separate the sample population from debris. The middle panel
represented the population selected for further analysis as it separated singlet beads
from aggregates, and the right panel represented the emission profile congruent with
Qdot 605 binding.
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Figure 4.19 shows data from samples containing no beads, but contained just RNA
and Qdot 605. The concern was that RNA-Qdot 605 that might not have been washed
away during the assay protocol and might be visualized as false positives during the flow
cytometry experiment. The results indicated that this detection did not exist as the flow
cytometer needs a physical particle to do a selection.

Figure 4.19 Sample four – biotinylated RNA and Qdot 605 diagram for possible
selection. The entire sample containing RNA-Qdot 605 conjugate (Event count 7) was
introduced into the instrument to determine whether selection could take place
increasing the likelihood of possible false positive results. As shown, there were no
samples shown to have an emission profile for Qdot 605.
Figure 4.20 shows data from samples containing the positive control incubated with
biotinylated RNA and Qdot 605. Focusing attention on the right panel, the peptide
samples contained Qdot 605 and the emission profile was altered compared to the
controls. Note that many of these beads did not show fluorescence despite the
expectation for binding to Qdot 605. This is likely due to two reasons. The first goes back
to the synthesis. Since there was no HPLC purification, beads likely contain failed
sequences/incomplete protective group cleavages, which may not bind to the RNA-Qdot
605 complex. The second may be due to the amount of RNA and Qdot 605 used in the
assay protocol. Addition of more RNA and Qdot may increase the amount of sample
bound for flow cytometry analysis. This outcome was observed for the rest of the
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samples discussed in this report and will be discussed in greater detail in the future
directions portion of this work.

Figure 4.20 Sample five – positive control peptide NQVANHQ with biotinylated
RNA and Qdot 605 diagram for flow cytometry detection. The left panel represents
the entire sample submitted (Event count 7034) for flow analysis with sample population
selected over debris. The middle panel represents the population of singlet beads
selected over aggregates for further Qdot 605 emission analysis. The selection was
consistent with previous samples submitted in this study. The right panel shows the
selected population with samples having Qdot 605 emission, indicative of RNA binding
to the peptide sample.
Also of significance is the population shown in the left panel of Figure 4.20. There is a
greater amount of debris particles of varying size and complexity compared to the
previous controls. This is due to the fact that synthetic peptide is present on each bead.
Ultimately, it changes the size and complexity based on how much peptide and the
different sequences available amongst different samples. It makes this selection process
more significant because fewer beads overall are selected for further analysis. We were
not concerned at this point because the goal was to first establish visualization of Qdot
605 emission.
Figure 4.21 shows data from the negative control. The negative control was the
peptide AAAAAAA incubated with biotinylated RNA and Qdot 605. This data was
different from the blank bead control because of the presence of synthetic peptide. The
population complexity increased (observed in the left panel), which meant that fewer
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beads were selected for further analysis. In the case of the negative control, 41% of the
original population was selected for further analysis of which approximately 88% of the
new population contained singlet beads that were acceptable for Qdot analysis. The
other main difference between the negative control and the blank bead control is the
population seen in the right panels of Figures 4.21 and 4.16. The blank bead control
(Figure 4.16) revealed a population closer to zero; whereas a 103 fluorescence intensity
was observed, indicative of greater autofluorescence. In general, beads without peptide
did not autofluoresce nearly as much as beads with peptide.

Figure 4.21 Sample six – negative control peptide AAAAAAA with biotinylated
RNA and Qdot 605 diagram for flow cytometry detection. The left panel represents
total sample introduction (Event count 4360) into the flow cytometer. The middle panel
shows the singlet population selected for further 605 nm emission detection. The right
panel shows the selected population (from the middle panel) with specific focus on Qdot
605 detection. Note that no Qdot 605 was detected.
Figure 4.22 shows a 1:1 mixture of the positive and negative control. Note that this
sample was produced independently of the individual positive and negative control; that
is, beads were not removed from the individual positive and negative controls and mixed
together. In addition to the screening, the brightest hits were individually placed into
individual wells of a 96-well plate for MS conformation of the identity of the peptide. Only
one plate containing 96 wells was used for the collection. It is interesting to see that a
greater population of the selected singlets revealed Qdot 605 emission. Although a 1:1
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mixture of positive and negative control beads were prepared, it seems that not many of
the negative control beads made it through the selection process, either because their
size and complexity was too different compared to the positive control or too much
aggregation had occurred preventing further selection and analysis.

Figure 4.22 Sample seven – mixture of the positive and negative control with
biotinylated RNA and Qdot 605 diagram for flow cytometry detection and sorting.
The left panel represents the entire sample introduced (event count 8111) to the flow
cytometer as well as the population gated away from debris. The middle panel
represents the singlet population selected from the total sample for further analysis. The
right panel shows the 605 nm emission profile for the samples.
Figure 4.23 shows samples of NQVANHQ, the parent sequence and are samples
from the same bead stock that was used for the positive control. Note that the samples
were from an independent preparation; that is, the beads were not pulled from the
positive control sample prep and submitted for sorting. This sample was also subjected
to sorting and one 96-well plate was used to collect beads with the brightest
fluorescence intensity indicative of binding to the 5'-Bi-H69ΨΨΨ and Qdot 605. There
were also a greater number of beads available for this sample (approximately 16,000)
compared to previous samples as such a greater population was observed in the debris
region of the initial gating. This means that the complexity and sizes of the beads varied
and only the beads that met the initial requirements for selection made it to the next
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round. In this case, approximately 51% of the beads introduced made it to the next
analysis board where singlets and aggregates were further separated.

Figure 4.23 Sample eight – NQVANHQ with biotinylated RNA and Qdot 605
diagram for flow cytometry detection and sorting. The left panel represents the
entire sample introduction (event count 15757) into the flow cytometry instrumentation.
An increase in the amount of debris and beads with differing complexity is likely due to
the increase in the number of beads introduced to the instrument relative to previous
samples. The middle panel represents the singlet population selected for further
analysis, and the right panel represents the emission profile of beads that fluoresce at
605 nm. Beads showing the brightest fluorescence were sorted into individual wells of a
96-well plate for later MS analysis.
Figure 4.24 shows samples of RQVANHQ, a modified H69 peptide that was identified
to have a higher affinity to the RNA studied in this work using ESI MS. Further
confirmation of binding to 5'-Bi-H69ΨΨΨ was desired and samples containing this
peptide were subjected to this assay and the brightest beads were selected for later MS
validation. Of particular interest in this set is that nearly 100,000 beads were available for
analysis, which is also why it is likely that only 6% of these beads showed Qdot 605
emission since incubation of the beads with Qdot 605 occurs on a vertical spinner in 0.5
mL Eppendorf tubes, it is unlikely that all beads were exposed equally to the fluorophore.
Compared to other samples submitted in which 5-10,000 beads were analyzed for Qdot
605 emission, there were approximately eight times more beads available and it was not
likely that there was enough room in the sample tube for the RNA and Qdot 605 to coat
all of those beads. The results are promising, but binding conditions need further
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optimization. Of the 78,328 beads analyzed for Qdot 605 emission, 4,762 beads (6%)
were positive hits. This result can be compared to sample eight, which showed 43% of
its beads with positive Qdot 605 emission (of 6,711 beads, 2,879 beads were positive
hits). There were more positive hits for RQVANHQ than NQVANHQ.

Figure 4.24 Sample nine – RQVANHQ with biotinylated RNA and Qdot 605 diagram
for flow cytometry detection and sorting. The left panel represents the entire sample
introduction (event count 96809) into the flow cytometry instrumentation. The middle
panel represents the singlet population selected for further analysis, and the right panel
shows the emission profile of beads that fluoresce at 605 nm. Beads showing the
brightest fluorescence were sorted into individual wells of a 96-well plate for later MS
analysis.
Figure 4.25 shows samples from a pool of position 1 variants containing a total of
seven different peptides. The rationale behind the design of this small pool of peptides
was to study the ability to identify peptides post-visual assay selection using mass
spectrometry. Identifying a small number of samples may not be efficient long-term, but
this approach was used for the purpose of testing the assay design. Variants in position
1 were made since previous ESI MS studies (Chapter 3) revealed that modification to
position 1 enhanced affinity to H69 RNAs. Of the 28,009 beads available for Qdot 605+
emission, 2,386 (9%) were positive hits. For flow cytometry selection, samples revealing
the beads highest intensity were sorted into a 96-well plate for later MS identification of
samples.
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Figure 4.25 Sample ten – position 1 variants with biotinylated RNA and Qdot 605
diagram for flow cytometry detection and sorting. The left panel represents the
entire sample introduction (event count 33566) into the flow cytometry instrumentation.
The middle panel represents the singlet population selected for further analysis, and the
right panel shows the emission profile of beads that fluoresce at 605 nm. Beads showing
the brightest fluorescence were sorted into individual wells of a 96-well plate for later MS
analysis.
4.3.4 Summary of flow cytometer results
The visual and physical selection of beads based on the secondary binding of
streptavidin-coated Qdot 605 to biotinylated RNA previously incubated with the peptide
was successful. Based off a "positive-hit" selection with the appropriate controls, this set
of experiments confirmed that variant RQVANHQ does bind to H69ΨΨΨ and that one or
more peptides from the position variant 1 pool also bind to H69ΨΨΨ.
To further support that RQVANHQ binds to H69ΨΨΨ RNA, the fluorescence intensities
were plotted against the positive and negative control as shown in Figure 4.26. As the
intensity of RQVANHQ is greater than that of the positive control, RQVANHQ is a
positive binder to H69 RNA. Position 1 variants also revealed positive binding indicating
that one or more peptides within than pool also bind to H69 RNA.
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Figure 4.26 Bar graph of Qdot 605+ emission detection. The fluorescence intensity
was determined for each sample selection and compared to the positive control. Any
value at or above one indicated a positive Qdot 605 profile indicative of positive binding
to H69 RNA.
Table 4.2 gives the event counts (beads) for each sample introduced into the flow
cytometer (panel 1), the number of singlets available for Qdot 605 detection (panel 2),
and the number of beads from each sample found to be positive Qdot 605 emission
(Qdot 605+) (panel 3). In the case of panel 3 Qdot 605+ detection, the percentage value
represents the percent of beads available for that event that led to Qdot 605+ detection.
For example, the RQVANHQ sample had 78,328 beads available for Qdot 605+
detection and 6% of those beads were positive for Qdot 605 meaning that 4,762 beads
from the 78,328 bead population were detected at 605 nm. These values should not be
taken as indicators for the degree of binding (weak vs. strong), but should be evaluated
on the presence of binding. Since the binding interaction is based on secondary binding;
that is, the fluorophore binds to the RNA which is already bound to the peptide bead, not
a direct binding of fluorophore to bead, it's important to optimize conditions by
consistently preparing the same approximate amount of beads and to incubate them
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with saturating amounts of RNA and Qdot 605 to assure that tight binders get sorted
during the flow cytometry experiment.
Table 4.2 Event counts of each sample for Qdot 605+ detection
Singlet Count
Event Count
(% selection
(% selection
Sample
Qdot 605
Sample Identification
for singlet
#
emission
count)
detection)
panel 1
panel 2
1
blank bead
25,000 (95%) 23,842 (89%)
2
blank bead + Qdot 605
25,000 (95%) 23,763 (91%)
3
blank bead + RNA
25,000 (94%) 23,637 (89%)
+Qdot 605
4
RNA + Qdot 605
7 (0%)
5
positive control
7,034 (70%)
4,933 (93%)
6
negative control
4,360 (41%)
1,776 (88%)
7
1:1 mixture of positive
8,111 (89%)
7,251 (91%)
and negative control
8
NQVANHQ
15,757 (51%)
8,019 (84%)
9
RQVANHQ
96,809 (92%) 89,192 (88%)
10
position 1 variants
33,566 (92%) 30,982 (90%)

4.3.5

Event Count
(% Qdot 605+
emission)
panel 3
21,269 (0%)
21,698 (0%)
21,134 (0%)
4562 (25%)
1,561 (0%)
6,587 (62%)
6,711 (43%)
78,328 (6%)
28,009 (9%)

Sample workup from the flow cytometry core

Samples with the brightest fluorescence from Figures 4.22 through 4.25, indicative of
Qdot 605-RNA-peptide binding, were placed into individual wells of a 96-well plate. Four
sample tubes (7-10) were submitted for sorting of the beads with the brightest emission
profiles at 605 nm and collected into 96-well plates. Each well plate (four total) was
exposed to UV irradiation at 365 nm as described in Section 2.8.4. After 1 h of
incubation under UV light, 50 μL of ddH2O, pH 7.2 was added to each well and the plate
was allowed to sit at room temperature for a minimum of 20 min in order to remove the
peptide from the surface of the well plate. Samples were placed into 0.5 mL autoclaved
polypropylene tubes, were dried in the speed vac, and stored in the -20 °C freezer for
later MS analysis.
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4.3.6

Mass analysis of peptides from the flow cytometry experiment

To determine whether the peptides could be identified directly from the Tentagel beads
used in the flow analysis, a mass spectrometry approach was taken. The long-term goal
is to obtain sequences of peptides from large randomized libraries. Highly sensitive
mass spectrometry instrumentation must be used for this process, since very little
peptide material is available from the individual bead. For this purpose, a collaboration
was established with Dr. Sarah Trimpin and her group.
Samples from plate one (96-well plate containing samples from the 1:1 positive and
negative control) as well as two samples from plate four (6 position 1 variants) were
tested for peptide identification/validation. Since this approach has not been used
before, most samples were used to optimize conditions. A SYNAPT G2 mass
spectrometer from Waters was modified by the Trimpin group to accept sample
crystallized with matrix. The sample was crystallized with either 3-nitrobenzonitrile
(3NBN) or 3,3'-dichlorobenzidine (DCB) matrix on a pipet tip, which was then placed
against the inlet aperture opening of the SYNAPT G2 mass spectrometer. The matrices
used did not require heat to increase ion abundance, which was ideal for this
experiment. Modifications to the mass spectrometer allow for lower heat configurations
when compared to traditional electrospray ionization mass spectrometers. The source
temperature used for all samples tested was 30 °C. The mass spectrometer
modifications and specifications unique to the Trimpin group was published in Analytical
Chemistry.233
To determine whether this instrumentation was suitable for this work, dried samples in
individual 0.5 mL autoclaved polypropylene tubes were dissolved in 2 μL of ddH2O, 50%
methanol, or 50% acetonitrile. The matrix, 3NBN or DCB (2 μL), was added to each
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dissolved sample for crystallization on the tip of a 200 μL pipet tip and exposed to the
mass spectrometer inlet for mass analysis. Both positive and negative ion modes were
employed in these optimization experiments. These steps were performed by Trimpin
lab member Dr. Christian Reynolds. Mass spectra were visualized using MassLynx V.
4.1 software and I processed the data using V. 4.0. Most data only showed mass
information for the matrix or artifact products that had no correlation with the peptide;
however, two samples did yield information from the peptide sample, which is discussed
in the following section.
Figure 4.27 shows the mass data obtained from a bead selected from sample seven
which contained a mixture of the positive and negative control peptides. In this case, the
positive control, NQVANHQ-NH2 photocleaved product, was observed. Note that no
liquid chromatography (LC) was used and the panel associated with LC was directly
related to the length of time that the pipet tip containing crystallized sample was exposed
to the MS inlet for mass detection. The amidated peptide product from ANP cleavage,
NQVANHQ-NH2, has an exact mass of 809.402 Da. The observed mass of 810.90 Da is
a minimum of 1 Da above the expected mass expected; however, upon further analysis,
the masses associated with the matrix as well as degraded product of the matrix are
also off by a minimum of 1 Da. No calibration was performed prior to the sample runs,
which may account for the +1 mass discrepancy. The highest intensity peaks of the
mass spectrum (top panel, Figure 4.28) are associated with degraded forms of the
matrix and were found in samples containing with the 3,3′-dichlorobenzidine (DCB)
matrix (m/z = 253.13).234 Dechlorination of DCB produced a degradation product that
can be identified at m/z = 217.234
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Figure 4.27 TOF MS of NQVANHQ-NH2 from one bead selected from sample seven
by flow cytometry. The mass spectrum (top) was isolated from the 0.78 time point of
the chromatogram (bottom right). The bottom left panel is associated with the expanded
region of the top panel revealing the identity of the peptide NQVANHQ-NH2 selected
from the flow cytometer.
The mass 202.934 appears to be the (4-) charge state of 810.901 associated with the
peptide product. The (2-) and (3-) charge states were observed as well; however, their
intensities were significantly lower and could not be separated from the noise. The (4-)
charge state of the peptide was visualized at a higher intensity than the (1-) charge.

133

Although these data do seem to identify the anticipated peptide mass, the amount of
material available for analysis may be too little for future sequencing experiments.
Plate 4 from the flow cytometry collection contained individual peptide samples from
the peptide library. It was not processed completely; that is, UV cleavage took place, but
50 μL of ddH2O was not added to each well yet in order to see if peptide analysis could
take place directly on the well plate. To get the peptide off of the plate, 2-5 μL of 1:1
acetonitrile in water was added to well A1 and mixed. The 3NBN matrix was added to
the sample for crystallization and the sample was analyzed in the positive-ion mode.
Figure 4.28 show data using this method, and although the results looks promising, this
was one of a few samples that were tested and this was the only sample that showed
discernable results. Based on the peptide library synthesized, the identity of the peptide
in this well was GQVANHQ-NH2. Other charge states were not observed for this sample
as was the case under the conditions represented in the last figure. It's unclear whether
there is enough sample to do sequencing analysis.
To further look at sensitivity of MS applications, MALDI-TOF MS was used to
determine whether detection of peptide from a single bead was possible. Samples were
dried down prior to spotting them on the MALDI-TOF MS target. The matrix α-cyano-4hydroxycinnamic acid was freshly produced as a saturated solution in 1:1 ACN in ddH2O
+ 0.1% TFA. Two μL was added to each sample and spotted in one allocated slot on the
target. This was carried out to concentrate the sample for optimum results. Interestingly,
peptides were observed using MALDI-TOF MS; however, with lower concentration,
intensity remained low increasing the signal-to-noise ratio. Note that other components
were observed in the sample since which was expected as purification could not be
performed prior to the assay or after the cleavage due to the probability of losing
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material during this process. Figure 4.29 shows MALDI-TOF MS data correlating to the
selection of a single 10 μm bead containing RQVANHQ from the flow cytometry
selection experiment.

Figure 4.28 Determination of unknown from a seven-membered pool containing
position 1 variants. The mass 376.23 is the (2+) charge state of GQVANHQ-NH2 (top),
observed from 0.63 minute point (bottom). This sample was obtained from flow
cytometry Qdot 605+ selection and was cleaved from a single 10 μm (dried) bead.
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Figure 4.29 MALDI-TOF MS of RQVANHQ from flow cytometry selection
experiments. A. MALDI-TOF MS spectrum of RQVANHQ from 96-well plate position
3A11. The sample spotted was obtained from a single 10 μm bead selected from flow
cytometry instrumentation based on the detection of Qdot 605 emission. The sample
was dried prior to addition of matrix and spotted in position C11 of the MALDI-TOF
target. B. An expanded view revealing the MH+ of RQVANHQ at 851.6 Da.
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To further study peptide obtained from bead sorting, MALDI-TOF MS was used to
observe peptide samples from beads that were subjected to RNA-binding and
subsequent flow cytometry. Figure 4.30 represents a 20 μL of beads in 1x PBS buffer
that were subjected to UV irradiation (365 nm) for 1 h and characterized using MALDITOF MS. As shown in this figure, individual masses correlating to the seven position 1
variants could not be easily identified due to the presence of crude material from the
original synthesis and the high signal-to-noise ratio.

Figure 4.30 MALDI-TOF MS of bead mixture pre-flow cytometry. A small sample of
beads were irradiated with UV light to cleave the peptide from the solid support. MALDITOF MS was used to determine whether the seven split-pool position 1 variants could be
identified.
Once the visual assay was completed and individual beads were sorted into a 96-well
plate by the flow cytometer, ten beads (10 μm) were cleaved (UV, 365 nm), combined,
and characterized using MALDI-TOF MS. Figure 4.31 shows MALDI-TOF MS data from
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the combined mixture of beads post-flow cytometry selection and it was interesting to
see that at least two peptides were detected from the selection (RQVANHQ and
PQVANHQ).

Figure 4.31 MALDI-TOF MS post-flow cytometry 10 bead (10 μm) mixture. Ten
beads sorted by the flow cytometer were cleaved, combined, and characterized using
MALDI-TOF MS. PQVANHQ had an observed MH+ mass of 756 Da and a predicted
MH+ mass of 756 Da. RQVANHQ had an observed MH+ mass of 851 Da and a predicted
MH+ mass of 851 Da.
4.3.7

Conclusions

CD experimentation provided evidence for conformational differences of the peptide
before and after binding to H69 RNAs. It seems that H69 peptides conformationally
change from a random coil configuration to a α-helical conformation and that this only
occurs with the unmodified H69 RNA. This is interesting because the parent sequence
was selected based on H69 wild-type binding and H69ΨΨΨ most closely represents this
original construct. It appears that the peptide retains its random coil structure upon
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binding to H69ΨΨΨ. It would be interesting to test other modified H69 peptides to
determine whether this trend is based on positional modification or upon binding to
H69UUU.
The visual assay and subsequent screening using flow cytometry instrumentation was
successful. Peptides were successfully synthesized on 10 μm beads, incubated with
biotinylated RNA followed by streptavidin-coated quantum dot (Qdot 605), and passed
through the flow cytometer. The cytometer was able to identify hits based on RNA and
Qdot binding. The parameter that needs to be further optimized is the concentration of
RNA and Qdot 605 added to the bead samples. Since bead samples are not uniform,
preparation is not consistent. Individual beads are impossible to see with the naked eye,
so the workup is done in a volume-based sample prep in 0.5 mL polypropylene tubes.
The tubes have markings on them giving approximate volumes and about 100 μL of
beads are added to each tube. As one can see from the data shown in this report, there
was a significant difference in the amount of beads screened in sample preparation. The
beads were not weighed out since so little material was needed for each sample
preparation, and it was important to avoid light as much as possible in order to avoid
premature cleavage of the UV linker. With these challenges, it was difficult to determine
just how much RNA and Qdot to add; however, this experiment suggests that increasing
the amount of each could provide more positive hits during the flow analysis. This is
discussed further in Chapter 6.
From the flow cytometer instrumentation side of the experiment, these beads were
often found aggregated or adhering to the side of the tubing (polyethylene) used for the
experiment. This could account for the inconsistency in sample bead available for each
screening. Incorporation of a 40 μm filter was used to prevent sample from getting stuck
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in the instrument, which would have prevented successful screening of the samples.
Even with these potential set-backs in flow cytometry, whether due to sample prep or
sample storage, the visual assay was a success and information obtained from this
experiment further validated binding of the parent sequence to H69 RNA as well as
provided further support that the modified H69 peptide RQVANHQ bound to the target
RNA. MALDI-TOF MS analysis has also provided evidence that information can be
obtained from a single bead (10 μm dried) selected from flow cytometry; however, it is
clear that the amount of material available is not enough for sequencing analysis.
Experiments that can help resolve this limitation are discussed further in the future
directions chapter (Chapter 6).
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CHAPTER 5 BINDING STUDIES BETWEEN HELIX 69 RNA AND AMINOGLYCOSIDE
ANTIBIOTICS198 ‡
‡ adapted from ref 198
5.1 Introduction
Although it has been previously established that aminoglycoside antibiotics bind
primarily to the A site (h44) of the small subunit of the bacterial ribosome235-236 and
translational processes by causing tRNA to misread mRNA codons,237 aminoglycosides
have also been found to bind to H69 of the large bacterial subunit.232, 238 This finding is
not surprising since H69 was previously shown to interact with h44 of the small subunit
at the interface of both the small and large bacterial subunits.13, 239-240
With the information already available, aminoglycosides have an established role in
translation inhibition and make secondary contacts with H69 of the large ribosomal
subunit. This led to the question of what, if any, conformational changes occurred when
these compounds bound to H69. As H69 is believed to be essential for ribosomal
function, it was important to investigate this question in order to learn more about this
motif. Dr. Yogo Sakakibara and Dr. Sanjaya Abeysirigunawardena had previously
revealed that H69 underwent structural rearrangements during ribosomal association or
with changing solution conditions with particular focus on positions A1913 and A1918.177178, 241

These nucleotide arrangements were influenced by Mg2+ concentrations, pH, and

temperature.177-178, 241 Position A1913 was already an implicated nucleotide important for
high-fidelity translation and efficient termination, which made it an interesting focus to
monitor aminoglycoside antibiotics, inducing conformational changes of H69.174, 242-243 Dr.
Sakakibara and Dr. Abeysirigunawardena investigated the conformational states of H69
RNAs by incorporating an adenine analogue, 2-aminopurine (2AP), at position 1913.198
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This analogue is often used to monitor ligand-induced RNA conformations due to its
ability to fluoresce when not stacked with other nucleotide bases.244-248 Figure 5.1 shows
the structures of 2AP and adenine.

Figure 5.1 Chemical structures of 2-aminopurine and adenine. 2-Aminopurine, left,
and adenine, right, are isomers of each other and have the same mass.
Figure 5.2 shows the secondary structures of the wild-type H69 and the modified and
unmodified H69 secondary structures with the incorporation of 2AP at position 1913.
These constructs enabled the conformational states of H69 to be monitored in solution.
Since the 2AP analogue is sensitive to changes in environment and undergoes
significant decreases in fluorescence intensity when base stacked, the fluorescence of
2AP was expected to diminish because of increased base stacking if nucleotide 1913
formed a local conformation similar to that observed in 50S subunits. An increase in
fluorescence intensity was expected if 2AP1913 became more exposed to solvent, as
seen in full 70S ribosomes.198
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Figure 5.2 Secondary structures of H69 RNAs with 2-aminopurine. Wild-type H69,
left is compared to the secondary structures of 2-aminpurine H69 (2AP-H69ΨΨΨ),
middle, and 2-aminopurine H69UUU (2AP-H69UUU), right. Modification to position 1913
from an adenine to a 2-aminopurine and a m3Ψ to a Ψ in position 1915 are the only
differences between the modified structures and the wild-type H69.
Drs. Sakakibara and Abeysirigunawardena used this established method to detect
conformational changes that occurred upon binding of the RNA to the aminoglycoside
antibiotic under different conditions and was able to determine apparent dissociation
constants for each aminoglycoside antibiotic tested with each H69 RNA. To support
these findings, ESI MS was performed on all of the H69 RNAs with neomycin and
paromomycin, and apparent dissociation constants were determined.
5.2 ESI MS binding studies with H69 RNAs and select aminoglycoside antibiotics
To obtain dissociation constants (Kds) for the aminoglycosides used in this binding
study, ESI MS was utilized. The instrumentation used can be found in Section 2.7.2 and
processed as described in Section 2.7.3. The protocol used to determine the
dissociation constants can be found in the published manuscript.198
Unmodified (H69UUU) and modified (H69ΨΨΨ) sequences of H69 (Section 2.4.1)
were used in addition to the incorporation of 2AP at position A1913 of both RNAs198
(2AP-H69UUU and 2AP-H69ΨΨΨ) giving a total of four RNAs to use in aminoglycoside
binding studies. The aminoglycosides neomycin and paromomycin were tested for
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binding with each H69 RNA. Unless otherwise stated, all figures associated with binding
results in Sections 5.2.1 through Section 5.2.4 are adaptions from the published
manuscript.198
5.2.1 ESI MS results of aminoglycoside binding studies with H69UUU
H69UUU is a 19-nucleotide stem-loop construct that contains three uridines in place of
the canonical pseudouridine (Ψ) in positions 1911, 1915, and 1917. Since the
modification exists only after post-transcriptional processes have occurred, this construct
is studied to determine similarities and differences in binding affinity and selectivity.
Binding experiments were performed with neomycin and paromomycin in duplicate
leading to the binding curves shown in Figure 5.3. Titration ESI MS spectra associated
with this plot can be found in Appendix B. The duplicate set of data revealed some
inconsistencies due to varying ionization efficiencies under different conditions. Dr.
Anne-Cecile Duc had previously tested the same construct with paromomycin to reveal a
dissociation constant of 8 ± 2, which was included in our publication.198 The binding
curves in Figure 5.3 revealed a 2.5-fold difference binding affinity in favor of neomycin
(1.4 μM) over paromomycin (3.7 μM). In comparison to the 8 μM Kd identified by Dr. Duc,
and supported by data found in Appendix B, there is a 6-fold difference in binding
affinity favorable to neomycin.
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Figure 5.3 Titration plots of neomycin and paromomycin bound to H69UUU.
Binding studies with H69UUU, neomycin, left, has a dissociation constant of 1.4 ± 0.6
μM. Paromomycin, right, has a dissociation constant of 3.7 ± 0.9 μM.
5.2.2 ESI MS results of aminoglycoside binding studies with 2AP-H69UUU
The second construct tested for binding was 2AP-H69UUU. The 2AP replaced the
A1913 of H69UUU construct. As discussed earlier in this chapter, 2AP is an analogue of
adenine; therefore, the mass of this construct is identical to that of H69UUU. Figure 5.4
represents the binding results of 2AP-H69UUU with neomycin and paromomycin,
respectively. Once again, neomycin binding led to greater binding affinity to 2APH69UUU (1.8 μM) over paromomycin (9 μM) with a 5-fold difference in apparent Kds.
Interestingly, these findings matched, within error, to the findings observed in Figure 5.3,
suggesting that the 2AP modification does not impact the binding ability of the
aminoglycosides to the RNAs.
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Figure 5.4 Titration plots of neomycin and paromomycin bound to 2AP-H69UUU.
Binding studies with 2AP-H69UUU, neomycin, left, has a dissociation constant of 1.8 ±
0.3 μM. Paromomycin, right, has a dissociation constant of 9 ± 3 μM.
5.2.3 ESI MS results of aminoglycoside binding studies with H69ΨΨΨ
The third construct tested with aminoglycosides was H69ΨΨΨ. This modified H69
construct contained three Ψ in positions 1911, 1915, and 1917. This is the closest
representation to the wild-type H69 as shown in Figure 5.2. Figure 5.5 represented
results from binding studies of H69ΨΨΨ with the aminoglycosides neomycin and
paromomycin. Neomycin bound to H69ΨΨΨ (1.2 μM) with an 8-fold greater affinity over
paromomycin (10 μM). As observed with the unmodified H69 counterparts, neomycin
appears to be a better binder than paromomycin.
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Figure 5.5 Titration plots of neomycin and paromomycin bound to H69ΨΨΨ.
Binding studies with H69ΨΨΨ, neomycin, left, has a dissociation constant of 1.2 ± 0.4
μM. Paromomycin, right, has a dissociation constant of 10 ± 3 μM.
5.2.4 ESI MS results of aminoglycoside binding studies with 2AP- H69ΨΨΨ
The fourth construct tested with aminoglycosides was 2AP-H69ΨΨΨ.The 2AP
modification replaced A1913 and is the only difference from H69ΨΨΨ. Figure 5.6
represented results from binding studies of 2AP-H69ΨΨΨ with the aminoglycosides
neomycin and paromomycin. A 7-fold difference in binding affinity was observed in favor
of neomycin bound to 2AP-H69ΨΨΨ (1.6 μM) over paromomycin (11 μM). These
findings correlate very well to the H69ΨΨΨ, without 2AP, with apparent Kds comparable
relative to the aminoglycoside binding; that is, neomycin binding to 2AP-H69ΨΨΨ (1.2
μM) and H69ΨΨΨ (1.8 μM) led to the same Kd, within error. This suggests that the 2AP
modification does not impact binding of the aminoglycosides as a difference in
dissociation constants was not observed. This finding was also observed with the
unmodified H69 counterparts with aminoglycoside binding.
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Figure 5.6 Titration plots of neomycin and paromomycin bound to 2AP-H69ΨΨΨ.
Binding studies with 2AP-H69ΨΨΨ, neomycin, left, has a dissociation constant of 1.6 ±
0.7 μM. Paromomycin, right, has a dissociation constant of 11 ± 3 μM.
5.2.5 Discussion of combined data from aminoglycoside H69 RNAs study
Aminoglycosides bound to the four H69 RNAs were studied using ESI MS. In the
previous sections of this chapter, data pertaining to each set of titrations were combined
and error was determined for each concentration of the aminoglycoside tested. Full
titration spectra corresponding with both aminoglycosides bound to each of the four H69
RNAs tested can be found in Appendix B of this work. This data provided evidence of
equal ionization efficiencies, with the exception of the binding studies associated with
H69UUU and paromomycin discussed earlier in this work, which supported the titration
plots described in previous sections of this chapter. Figure 5.7 gives a one-shot view of
each RNA bound to neomycin at or near the calculated dissociation constant.

As

shown, the intensity peaks associated with the free RNA at the (4- ) charge state and the
neomycin-RNA (4-) have similar heights. When comparing to the overall titration spectra
found in H69 RNAs, in Appendix B, one will see that with increasing concentration of
neomycin, the free RNA peak would decrease with increasing complex formation of
neomycin bound to the RNA.
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Figure 5.7 One-shot profiles for H69 RNAs bound to neomycin. Each spectrum
within this figure shows a concentration of neomycin closest to the dissociation constant
plotted in Figures 5.3 through 5.6. The complex formation peak intensity is nearly if not
the same height as the free RNA at the (4-) charge site which correlated with the
apparent dissociation constant obtained from a duplicate set of titrations for each RNA
and neomycin.
Figure 5.7 provides an important finding in that the incorporation of 2AP had no impact
on the apparent dissociation constant making it a suitable analogue for binding studies.
The similar Kds between the 2AP- and A-containing constructs were important because
the values for 2AP-H69UUU and 2AP-H69ΨΨΨ were about the same. In contrast
difference in fluorescence was observed for 2AP-H69UUU and 2AP-H69ΨΨΨ. This
result revealed that the conformational changes observed between 2AP-H69UUU and
2AP-H69ΨΨΨ do not impact the overall dissociation constants. In other words, a
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mechanism-based assay vs. straight Kd measurement are combined to gain a deeper
understanding of the binding mode. More specifically, the use of both ESI MS and
fluorescence-based studies was critical for understanding the base flipping of A1913
upon aminoglycoside binding.
Paromomycin yielded apparent dissociation constants with titration spectra showing
near-equivalent ionization efficiencies of aminoglycoside-RNA binding versus free RNA.
Figure 5.8 gives a one-shot profile of each RNA bound to paromomycin near its
calculated dissociation constant. Despite the higher dissociation constants to H69 RNAs
compared to neomycin binding studies, paromomycin revealed similar binding trends to
H69 RNAs; that is, overlapping Kds were observed with 2AP-H69ΨΨΨ (11 μM) and
H69ΨΨΨ (10 μM) and with 2AP-H69UUU (9 μM) and H69UUU (8 μM, obtained by Dr.
Duc198), respectively. This adds further evidence with a different aminoglycoside
antibiotic that changes in fluorescence should be compared to other binding
measurements such as ESI MS.
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Figure 5.8 One-shot profiles for H69 RNAs bound to paromomycin. Each spectrum
within this figure shows a concentration of paromomycin closest to the dissociation
constant plotted in Figures 5.2 through 5.5. The complex formation peak intensity is
nearly if not the same height as the free RNA at the (4-) charge site which correlated
with the apparent dissociation constant obtained from a duplicate set of titrations for
each RNA and paromomycin.
To further visualize the similarities of apparent dissociation constants, Table 5.1
combines the dissociation constants obtained from ESI MS and compares them to the
dissociation constants obtained from Dr. Sakakibara's fluorescence data testing the
same products. What was of interest is the similarity in apparent dissociation constants
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despite the difference in the techniques used to obtain them. Of particular interest is the
fact that the dissociation constants found using ESI MS were similar to those found
using fluorescence-based techniques. This comparison provides evidence that despite
the RNA used or the aminoglycoside tested, the incorporation of 2AP into an RNA did
not impact the overall result making this technique combination useful in studying the
binding modes of RNAs and their ligands.198
Table 5.1 Aminoglycoside binding with H69 RNAs198
Ligand
Method
RNA type
Kd [μM]
2AP-H69ΨΨΨ
fluorescence
2.5 ± 0.2
2AP-H69ΨΨΨ
ESI MS
1.6 ± 0.7
H69ΨΨΨ
neomycin
ESI MS
1.2 ± 0.4
fluorescence
2AP-H69UUU
2.0 ± 0.4
ESI MS
2AP-H69UUU
1.8 ± 0.3
ESI MS
H69UUU
1.4 ± 0.6
2AP-H69ΨΨΨ
fluorescence
7±1
2AP-H69ΨΨΨ
ESI MS
11 ± 3
H69ΨΨΨ
paromomycin
ESI MS
10 ± 3
fluorescence
2AP-H69UUU
ND
ESI MS
2AP-H69UUU
9±3
5.3 Determination of a dual-binding mode between a H69-selected peptide with
H69 RNAs and neomycin
Crystallography and model studies have been done with H69 RNA and
aminoglycosides revealing that aminoglycosides have a secondary target site to the
stem region of H69.232, 238 As discussed in Chapter 3, H69 peptides have been shown to
bind to the loop region since evidence has shown that there is selectivity of many of the
peptides to H69ΨΨΨ over H69UUU. Hypothetically, it may be possible that a dualbinding mode of a H69 peptide and neomycin bound to H69 RNA is possible. The one
possible limitation would be that binding of the aminoglycoside could alter the overall
conformational state of the RNA making a binding interaction with the peptide unlikely or

152

that a higher concentration of peptide would be necessary to visualize a binding
interaction.
Experiments were performed and analyzed using ESI MS as described in Section
2.7.2 and Section 2.7.3. Neomycin concentration was maintained at 10 μM, H69 RNA at
2.7 μM, and peptide concentrations varied from 0 to 100 μM (five to six different
concentrations). Although a mass peak associated with 1:1:1 binding of the RNA,
neomycin, and peptide was observed earlier on in the titration, it was visualized clearly
at 60 μM NQVANHQ-NH2 as shown in Figure 5.9.

Figure 5.9 An ESI MS spectrum revealing a 1:1:1 complex of H69UUU RNANeomycin-NQVANHQ-NH2. This spectrum revealed a profile of which free H69UUU,
peptide dimer, a 1:1 H69UUU-neomycin, and 1:1:1 H69UUU-neomycin-NQVANHQ-NH2
complex at the (4-) charge state was observed.
The experiment was repeated with H69ΨΨΨ RNA (2.7 μM), neomycin (10 μM), and 0 100 μM NQVANHQ-NH2 (five to six different concentrations). The same complex was
visualized at 40 μM NQVANHQ-NH2 as shown in Figure 5.10. Titrations pertaining to
these binding studies did not yield usable information to determine apparent dissociation
constants mostly due to the increase in noise with higher peptide concentrations and the
already high concentration of neomycin used during the study. The fact that no peptideneomycin peak was observed is promising assuring that the peptide is indeed binding to
RNA independently of the aminoglycoside.
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Figure 5.10 ESI MS spectrum revealing a 1:1:1 complex of H69ΨΨΨ RNANeomycin-NQVANHQ-NH2. This spectrum revealed a profile of which free H69ΨΨΨ, a
1:1 H69ΨΨΨ-neomycin, and 1:1:1 H69ΨΨΨ-neomycin-NQVANHQ-NH2 complex at the
(4-) charge state was observed.
5.4 Future directions
Aminoglycoside binding studies using ESI MS provided useful information that could
be of use in future projects with H69-selected peptides. Since it is not likely that small
heptameric peptides will make viable drugs, binding studies with aminoglycosides
provide a possible resolution toward making the peptides identified to target H69 RNAs
more "druggable". A possible direction to take the information provided in this chapter
would be to conjugate H69 peptides to aminoglycosides or portions of aminoglycosides
necessary for selective binding. In the case of aminoglycosides, the neamine core would
be an excellent start for conjugation experiments. This fragment-based drug design
approach could be tested with ESI MS as well as other biophysical techniques (NMR,
ITC, CD) leading to both structural and quantifiable data regarding selectivity, binding
location, and binding affinity.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS
6.1.1 The use of ESI MS to determine roles of peptidic side chains in RNA binding
interactions
Chapter 3 provided evidence to support the use of modified peptidic ligands to target
H69 RNAs. The ESI MS technique provided information regarding binding affinity,
selectivity, and apparent dissociation constants of each modified peptide bound to H69
RNAs. This technique provided useful information with regard to which positions of the
heptamer contributed to H69 RNA binding, allowing an opportunity to design novel
peptides with increased selectivity and affinity to the target RNA (Figure 6.1).

Figure 6.1 Summary of H69 RNA binding with peptide modifications. Modified
(H69ΨΨΨ) and unmodified (H69UUU) H69 RNAs underwent binding studies with
modified H69 peptides using ESI MS. For H69ΨΨΨ, changes at positions 1 and 6
yielded modified peptides with greater affinity than the parent sequence. Positions 2 and
3 (red) gave apparent dissociation constants in the same range as the parent sequence.
Numeral values give an x-fold difference in affinity when compared to H69UUU.
H69UUU results suggested that modifications in positions 1, 3, 5, and 6 could lead to
peptides with greater affinity to unmodified H69 when compared to the modified parent
RNA. Position 4 and 7 variants had similar apparent dissociation constants when
compared to the parent peptide.
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H69ΨΨΨ, the modified RNA sequence closest to the wild-type construct, demonstrated
greater binding affinity to two modified peptide variants, RQVANHQ-NH2 and
NQVANRQ-NH2, when compared to the selected parent sequence, NQVANHQ. Based
on the ESI MS results, modifications at position 1 and 6 with alanine led to either very
poor or no observable binding to the H69 RNAs. In addition, RQVANHQ-NH2 had a 4fold greater affinity to the modified construct over H69UUU, revealing modest selectivity
for H69ΨΨΨ. Similarly, NQVANRQ-NH2 had a 3-fold greater affinity for H69ΨΨΨ over
H69UUU. Modifications at positions 2 and 3 to alanine produced peptides with similar
apparent dissociation constants to the parent sequence; however, position 2
(NAVANHQ-NH2) had a 12-fold greater affinity for H69ΨΨΨ over H69UUU, further
supporting selectivity to the H69 RNA closest in composition to the wild-type sequence
that was used to identify the parent peptide in phage-display experiments.197 It is
important to have selectivity to the modified construct over the unmodified since the only
difference between the two is the presence of Ψ, a post-transcriptional modification that
has implicated roles in several essential processes as discussed in Chapter 1. To
collect further evidence of these roles, studying the modified nucleosides is important,
which is why designing peptides that selectively target modified H69 is imperative for
solving this challenge.
H69UUU, an unmodified H69 RNA (no Ψ), demonstrated greater affinity for several of
the modified peptides than modified H69 when compared to the parent peptide
sequence. In particular, modifications at positions 1, 3, 5, and 6 led to modified variants
with greater affinity for H69UUU. Changes at positions 4 and 7 led to modified peptide
variants with similar dissociation constants as the parent sequence for H69UUU. The
ability to generate modified variants capable of binding to H69UUU with higher affinity
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than NQVANHQ suggests that the loop region is the primary target since these findings
were different than those obtained with H69ΨΨΨ. These findings suggest that these
modified H69 peptides target modified nucleotides present within the H69 construct. It
would be useful to have H69UUU-targeting peptides in order to potentially reveal
mechanistic functions of H69 prior to post-transcriptional modification.
6.1.2 Using mass spectrometry to determine binding locations and binding
affinities of modified peptides targeting H69 RNAs
ESI MS provided useful information regarding binding affinity and selectivity within the
determination of apparent dissociation constants. Although this technique provided
opportunities for quantitative analysis of these binding interactions, mass spectrometry
could be further used to determine the binding location. Utilizing an MS/MS
bombardment approach could provide information regarding the binding location by
studying fragments obtained from the mass experiment.249-257 The experiment would
begin by incubating the modified peptide variant with the target RNA. Bombardment of
the sample would produce fragments; however, complex formation between the peptide
and RNA remain intact.249-257 Knowing the masses and chemical formulas of each
component makes identification of complex between peptide and RNA fragment
possible, which would then provide a binding location(s) of the peptide on the target
RNA.249-257 Another mass technique that could be used to gain the same information is
one developed by Dr. Patrick A. Limbach in which nucleases are utilized on samples and
subsequent mass analysis provides fragments without the need for hard ionization
techniques.258 Mass spectrometry could provide invaluable information and should be
further explored in the study of peptide – RNA interactions.
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6.2.1 Biophysical binding studies of selected H69 peptides
Biophysical techniques such as circular dichroism (CD) and isothermal titration
calorimetry (ITC) provide different, but complementary, information regarding peptideRNA binding complexes. CD experimentation has the ability to reveal the differences in
conformation between complexed and uncomplexed RNA and peptide moieties, and ITC
experimentation has the ability to provide absolute binding constants under
physiologically relevant better conditions. Although both of these techniques were used
in this work, complications led to the necessity for further optimization. CD experiments
revealed that the global conformation of RNA remained unchanged upon peptide
binding; however, studies with H69UUU revealed the conformational changes between
that of bound peptide (α helix) and unbound peptide (random coil). These differences
were not observed with the modified RNA construct. ITC experiments did provide
evidence that an exothermic reaction took place upon binding of RNA and peptide;
however, binding constants could not be determined based on the conditions used.
The development of a screening assay utilizing flow cytometry provided evidence
supporting modified peptide binding to H69ΨΨΨ RNA. This assay depended on
secondary binding between RNA and peptide simultaneously bound to a fluorophorecontaining entity (Qdot 605). Flow cytometry was able to not only identify individual
beads emitting at 605 nm, but also sorted the brightest hits for mass analysis and
subsequent peptide identification. These findings are promising because they can
expedite the identification of novel peptide ligands targeting RNA for further biophysical
and biochemical analysis.
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6.2.2 Expanding on biophysical binding studies of selected H69 peptides
Biophysical studies besides mass spectrometry provided some evidence regarding
RNA and peptide binding; however, further optimization is necessary to give more
conclusive results. In the case of circular dichroism, it would be interesting to test other
peptide variants to determine whether modification position vs. the binding to the H69
RNA construct (H69ΨΨΨ or H69UUU) is important for conformational changes. ITC
results revealed an exothermic reaction indicative of a chemical interaction (binding
event) having taken place; however, although this technique is capable of providing
absolute binding constants, that was not achieved in this case. Since endogenous salt in
the peptide sample is likely the culprit and removal of the salt was challenging, it might
be worth doing a titration in which the peptide resides in the sample cell and the RNA in
the syringe. This role reversal may provide novel information despite the salt
concentration within the peptide sample.
An alternative approach involves further modification of the peptide, thereby providing
a sequence that can be desalted and studied. For instance, modifying position 3 to a
phenylalanine could provide a sequence that could be desalted without disturbing
binding to the RNA. ESI MS studies revealed that modifications to alanine and arginine
at residue 3 led to promiscuous binding, suggesting the need for a bulky nonpolar group
for selective binding to H69 RNA. Modifying this position with an aromatic amino acid
would allow improved HPLC purification and desalting since aromatic functional groups
elute at higher ACN concentrations (30%). Prior to ITC experimentation, ESI MS studies
should be performed with this modified variant and H69UUU and H69ΨΨΨ. This
approach would allow determination of whether the modification has binding affinity and
selectivity comparable to previously selected peptides and whether ITC experiments
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should be performed. If ESI MS validates the usefulness of the modified variant, ITC
experiments could be further optimized with ligand devoid of endogenous salt, and a
buffer match between the peptide and RNA could be maintained.
Additionally, biochemical experimentation such as enzymatic footprinting could be
used for these studies. Enzymatic footprinting works on the premise that nucleases have
predicted cleavage or hydrolyzing patterns on nucleic acids that are disrupted when the
nucleic acid is complexed with a ligand. These reactions are monitored using
radiolabeled nucleic acids monitored by gel electrophoresis. Furthermore, titrations of
the ligand and target can provide dissociation constants for modified peptides.216 These
experiments were performed, but findings were inconclusive. The greatest challenge
was the inability to consistently quench the nuclease, which often led to over-digestion of
the RNA. The use of an RNAse inhibitor would aid in resolving this challenge and could
yield conclusive findings.
The visual assay provided very promising results, giving additional evidence that
binding between modified peptides and H69ΨΨΨ did occur; however, more could be
done to increase the sensitivity of detection of the fluorophore. Designing a compound
that could be used as a calibrant would provide more information regarding the number
of fluorophore moieties that had bound to an individual bead. This value could be
extrapolated and compared to samples containing randomized peptide libraries in which
not only 605 nm emission is detected. Knowing the number of fluorophore molecules
bound to a single bead would lead to stricter selection parameters, which would allow
sorting of individual beads with the highest signal intensity to take place.
Another parameter that should also be optimized for the flow cytometry experiment is
the amount of sample submitted. Ideally, samples should be incubated with saturating
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amounts of RNA and fluorophore in order to assure complete binding to each possible
site available. Samples were previously prepared by a visual dependence on the volume
markings on the sample tubes with the assumption that the beads associated with each
sample were the same in size. Dried samples could be weighed on sensitive precision
balances, and the amount of peptide material available for flow analysis could be better
approximated. This approach would give a better indication of how much RNA and
fluorophore to add leading to the optimal concentration of reagents per sample
submission.
This flow cytometry assay is promising; however, it would be more effective if large
randomized libraries could be synthesized and tested with the assurance that peptide
sequencing could take place after sorting. There are two limitations preventing the
current set of peptides from being sequenced. The first is that the flow cytometer cannot
accept beads greater than 100 μm in size forcing the usage of smaller beads (10 μm).
The second is that the amount of material on the bead is very low (fmol) and insufficient
for reliable sequencing. Since beads swell to a minimum of three times their dried size
and synthesizing material onto them adds to their size, one is limited to small beads (10
μm) with low capacity (0.23 mmol/g). If a high-loading resin could be produced with a
more compact size, more material would be available for sequencing and this challenge
would be solved. RAPP-polymere has produced high capacity beads that remain small
in size. For instance, the 75 μm beads have the same capacity (0.48 mmol/g) as the 140
μm beads which are nearly double in size. If this could be applied to an even smaller
bead, this assay would be more effective. A second option would be to test other beads;
that is (e.g. 20 and 30 μm) and solvents for peptide synthesis to vary the degree of
swelling. It may be possible to work with a larger bead with greater capacity without
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exceeding the 100 μm limitation. Preliminary findings have determined that total mass
identification is possible from material on a single bead; it's now a matter of attaining
enough material to do sequencing, which would make this assay optimal for large-scale
selections.
6.3.1 Binding studies between helix 69 and aminoglycoside antibiotics led to the
establishment of a dual binding mode of aminoglycoside and peptides to helix 69
RNAs
ESI MS binding studies were performed with modified and unmodified H69 RNAs with
and without 2-aminopurine in position A1913.198 The dissociation constants correlated
well with dissociation constants obtained using fluorescence-based techniques
performed by Dr. Yogo Sakakibara, which showed the value in using two techniques for
comparison because they give complementary information such as stoichiometry vs.
conformational changes.198 Crystallography and model studies have been done with H69
RNA and aminoglycosides, revealing that aminoglycosides target the stem region of
H69.232, 238 As discussed in Chapter 3, H69 peptides have been proposed to bind to the
loop region, there is selectivity of many of the variants to H69ΨΨΨ over H69UUU.
Aminoglycoside antibiotic binding studies with H69 RNAs led to additional experiments
with peptides. Results revealed 1:1:1 binding complexes with RNA, neomycin, and
peptide. These findings were not limited to H69ΨΨΨ, but also demonstrated with
H69UUU. Also of interest was the absence of aminoglycoside-peptide peaks, suggesting
that these small compounds bind to RNA independently.
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6.3.2

A

fragment-based

drug

design

approach

for

producing

peptide-

aminoglycoside compounds for H69 binding studies
ESI MS studies gave supporting data that a 1:1:1 binding complex with RNA-peptideaminoglycoside exists. Docking studies using PDB files of known crystal structures of
the bacterial ribosome can be used to study possible conjugation profiles between the
neamine core of aminoglycosides and winner peptides. This modeling approach could
provide

the

best

synthetic

direction for

compounds

containing

peptide

and

aminoglycosides. With the successful synthesis of such compounds, ESI MS could be
used to attain apparent dissociation constants, which would provide valuable information
that could be applied to in vivo applications such as ribosomal inhibition assays and MIC
studies.
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APPENDIX A: ESI MS TITRATION DATA FOR H69 MODIFIED PEPTIDES WITH H69
RNAS
This appendix contains ESI MS titration spectra correlating to results shown in Chapter
3 of this work.
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Table A1 Peptide sequence and molecular formula for mass determination

Peptide Sequence

Molecular Formula

Mass Lynx V.4.0
Molecular
Weight

RQVANHQ-NH2
NRVANHQ-NH2
NQRANHQ-NH2
NQVRNHQ-NH2
NQVARHQ-NH2
NQVANRQ-NH2
NQVANHR-NH2
AQVANHQ-NH2
NAVANHQ-NH2
NQAANHQ-NH2
NQVANHQ-NH2
NQVAAHQ-NH2
NQVANAQ-NH2
NQVANHA-NH2

C34H58N16O10
C33H56N16O10
C33H55N17O11
C35H59N17O11
C34H58N16O10
C32H57N15O11
C33H56N16O10
C31H51N13O10
C30H49N13O10
C30H48N14O11
C32H52N14O11
C31H51N13O10
C29H50N12O11
C30H49N13O10

850.5
836.4
865.4
893.5
850.5
827.4
836.4
765.4
751.4
780.4
808.4
765.4
742.4
751.4

Table A2 H69 RNAs
Sample
H69UUU/H69ΨΨ
Ψ
5'-Bi-H69UUU/
5'-Bi-H69ΨΨΨ

Molecular Formula

Molecula
r
Weight

(3-)

(4-)

(5-)

C181H225N73O130P18

6057.9

2018.3

1513.5

1210.6

C197H253N76O135P19S

6463.0

2153.3

1614.7

1291.6
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Figure A1 AQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM. Biotinylated modified RNA (5'-Bi-H69ΨΨΨ) was used to
enhance the intensities of peptide-RNA complex.
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Figure A2 AQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM. Biotinylated modified RNA (5'-Bi-H69ΨΨΨ) was used to
enhance the intensities of peptide-RNA complex.
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Figure A3 AQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A4 AQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A5 NAVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A6 NAVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A7 NAVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A8 NAVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A9 NQAANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A10 NQAANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A11 NQAANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A12 NQAANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A13 NQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.

180

Figure A14 NQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A15 NQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A16 NQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A17 NQVAAHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A18 NQVAAHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A19 NQVAAHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A20 NQVAAHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A21 NQVANAQ-NH2 with H69UUU set 1 of 1. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 120 μM.
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Figure A22 NQVANAQ-NH2 with 5'-Bi-H69ΨΨΨ set 1 of 1. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 100 μM.
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Figure A23 NQVANHA-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
100 μM.
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Figure A24 NQVANHA-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
100 μM.
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Figure A25 NQVANHA-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A26 NQVANHA-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A27 RQVANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
50 μM.
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Figure A28 RQVANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
50 μM.
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Figure A29 RQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A30 RQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A31 NRVANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A32 NRVANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.

199

Figure A33 NRVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A34 NRVANHQ-NH2 with H69ΨΨΨ 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 60 μM. Biotinylated modified H69 RNA (5'-Bi-H69ΨΨΨ) was
added to enhance the intensity of the peptide-RNA complex.
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Figure A35 NQRANHQ-NH2 with 5'-Bi-H69UUU set 1. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 50 μM.
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Figure A36 NQRANHQ-NH2 with 5'-Bi-H69UUU set 2. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 50 μM.
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Figure A37 NQRANHQ-NH2 with 5'-Bi-H69ΨΨΨ set 1. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 60 μM.
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Figure A38 NQRANHQ-NH2 with 5'-Bi-H69ΨΨΨ set 2. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 60 μM.
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Figure A39 NQVRNHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A40 NQVRNHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.

207

Figure A41 NQVRNHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A42 NQVRNHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
60 μM.
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Figure A43 NQVARHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A44 NQVARHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A45 NQVARHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A46 NQVARHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A47 NQVANRQ-NH2 with H69UUU set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A48 NQVANRQ-NH2 with H69UUU set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A49 NQVANRQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A50 NQVANRQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through
120 μM.
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Figure A51 NQVANHR-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A52 NQVANHR-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations
ranged from 0 through 120 μM.
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Figure A53 NQVANHR-NH2 with 5'-Bi-H69ΨΨΨ set 1. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 120 μM.

220

Figure A54 NQVANHR-NH2 with 5'-Bi-H69ΨΨΨ set 2. ESI MS titration spectra
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0
through 120 μM.
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APPENDIX B: ESI MS TITRATION DATA FOR H69 RNAS WITH AMINOGLYCOSIDE
ANTIBIOTICS
This appendix contains ESI MS titration spectra correlating to results shown in Chapter
5 of this work.
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Table B1 Sample molecular formulas for mass determination
Molecular
Formula
Exact Mass
(3-)
Sample
H69UUU/H69ΨΨΨ
C181H225N73O130P18
6057.9
2018.3
2AP-H69UUU/
C181H225N73O130P18
6057.9
2018.3
2AP-H69ΨΨΨ
Biotin of RNA
405.1
C16H28N3O5SP
Paromomycin
615.3
C23H45N5O14
Neomycin
C23H46N6O13
614.3

(4-)
1513.5

(5-)
1210.6

1513.5

1210.6
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Figure B1 Paromomycin with H69UUU set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with H69UUU RNA.

224

Figure B2 Paromomycin with H69UUU set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with H69UUU RNA.
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Figure B3 Neomycin with H69UUU set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with H69UUU RNA.
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Figure B4 Neomycin with H69UUU set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with H69UUU RNA.
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Figure B5 Paromomycin with H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with H69ΨΨΨ RNA.
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Figure B6 Paromomycin with H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with H69ΨΨΨ RNA.
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Figure B7 Neomycin with H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with H69ΨΨΨ RNA.
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Figure B8 Neomycin with H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with H69ΨΨΨ RNA.
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Figure B9 Paromomycin with 2AP-H69UUU set 1. Aminoglycoside antibiotic at
varying concentrations is titrated with 2AP-H69UUU RNA.
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Figure B10 Paromomycin with 2AP-H69UUU set 2. Aminoglycoside antibiotic at
varying concentrations is titrated with 2AP-H69UUU RNA.
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Figure B11 Neomycin with 2AP-H69UUU set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with 2AP-H69UUU RNA.
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Figure B12 Neomycin with 2AP-H69UUU set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with 2AP-H69UUU RNA.
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Figure B13 Paromomycin with 2AP-H69ΨΨΨ set 1. Aminoglycoside antibiotic at
varying concentrations is titrated with 2AP-H69ΨΨΨ RNA.

236

Figure B14 Paromomycin with 2AP-H69ΨΨΨ set 2. Aminoglycoside antibiotic at
varying concentrations is titrated with 2AP-H69ΨΨΨ RNA.

237

Figure B15 Neomycin with 2AP-H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying
concentrations is titrated with 2AP-H69ΨΨΨ RNA.

238

Figure B16 Neomycin with 2AP-H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying
concentrations is titrated with 2AP-H69ΨΨΨ RNA.
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In the development of peptide ligands to target H69, SPPS and ESI MS was used to
determine if 1) peptides could bind to modified H69 and 2) if increased affinity for the
target RNA could be enhanced with modification. An alanine and arginine scan was
synthesized and tested for this determination. Selected peptides were then tested using
biophysical techniques such as circular dichroism and isothermal titration calorimetry. An
assay was also designed to increase the efficiency of peptide ligand selection in which
novel peptides with high affinity and selectivity could be identified for future projects. This
assay was done using flow cytometry, instrumentation capable of identifying beads,
bound to the target RNA conjugated to a fluorophore, based on fluorophore emission,
and sorting them into 96-well plates for MS analysis.
The last part of the research focused on aminoglycoside-H69 RNA interactions. ESI
MS was used to obtain binding affinities and stoichiometries of 2AP- and A-containing
H69 RNAs. The findings revealed that the binding mode had not changed between these
two sets of RNAs, which revealed the value for using ESI MS in combination with other
techniques, such as fluorescence, to give a complete picture of the binding mode
(stoichiometry, affinity, selectivity) in comparison with conformational changes that may
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occur upon binding. Further exploration of aminoglycoside-H69 RNA interactions took
place with the H69 peptide NQVANHQ-NH2 to determine whether a fragment-based
drug design approach could be used to create small compounds for future in vivo
applications.
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